Medical Device ASIA, November-December 2015 issue

Page 1

Vol.7 No.6 | November-December 2015 | New Delhi

PROTEIN

Packaging PHARMACEUTICAL Revolutionary Air Purifiers Sugar disease In India

AWARENESS CAMPAIGN

Merck Brand Relaunched New Launch! Veterinary hematology analyzer

Vitamin Deficient Indians

! w Ne Portable Anaesthesia Machine

MEDICAL FAIR ASIA ‘s

MEDICINE + SPORTS CONFERENCE in 2016



e d i t o r i a l

h i g h l i g h t s 4

Vol.7 No.6 | November-December 2015 |Annual Suscription: Rs.2,000 | Overseas: US$250

6 10 13 20 22 24 26 32 33 35 37 40 45 50 52

MEDICAL FAIR ASIA to host inaugural Asian edition of MEDICINE + SPORTS CONFERENCE in 2016 International Medical Devices and Supplies Fair Ends MEDICA and COMPAMED - Show Report Air Liquide Medical Systems Sharpís Revolutionary Air Purifiers Helps Prevent Airborne Diseases New Rigel 288 safety analyser is a big Plus for faster medical device testing Sugar disease growing at alarming rate in India POULTRY INDIAíS PROTEIN AWARENESS CAMPAIGN Merck Brand Relaunched 7 out of every 10 Indians are Vitamin deficient: Metropolis Study MEDICAL FAIR ASIA 2016 MediAngels bags Healthcare Excellence Award Diatron to launch new 5-part veterinary hematology analyzer at Medica Aarogyam Energy Jewellery Kamani Oils receives FDA License Introducing a Safer Hand Sanitizer with Lasting Protection!

Indian medical device industry Growth to 2016

T

he Indian medical device industry has a potential to grow from current $4.4 billion to $7 billion by 2016, a premier US-India business body has said as it called for a dialogue with the government to address issues of ease of doing business. The medical device industry, having enjoyed fast growth and healthy profits for many years, faces much tougher times ahead. The industry is operating in a drastically changed environment with reduced government funding exacerbating the difficulties. Europe’s medical device industry: leadership challenges in a changing world, reveals that more innovative talent strategies are required to deliver solutions that not only improve patients’ health but also reduce overall healthcare costs. A proactive talent strategy is essential: in many cases, companies need to look outside their own industry to enhance their leadership bench-strength and to remain competitive while coping with high-levels of change. India is a land full of opportunities for players in the medical devices industry. The Indian hospital services generated revenue of more than US$ 45 Billion in 2012. This revenue is expected to rise at a CAGR of 20%

during 2012-2017 generating immense possibilities for players in the market. Besides, Indian medical service consumers have become more conscious towards their healthcare upkeep. Thanks to India’s economic growth and a rise in penetration of medical insurance, the 300 Million plus middle class population of India can now afford almost any of its healthcare needs. Such a scenario presents immense opportunities for players in the medical devices business. Currently, import constitutes almost 70% of the Indian medical devices market. A historical trend analysis of the total import value of medical devices in India shows that despite a depreciating currency, the trend to import has remained positive. For RNCOS’ study, the company analysts have conducted a thorough trend analysis of medical device imports in the country. What medical devices are majorly imported; what are the key drivers behind their import; and what are the challenges that imports of these medical devices face; such and other factors depicting the overall scenario of medical device imports in the country are provided in the report. Similar facts have been reported for exported and locally manufactured medical devices, providing a complete picture of the Indian medical devices industry. Research findings from the study will help players in identifying distinct opportunities. They will get an insight on which medical devices are exported to which countries. Also, local players will get to know which medical devices are majorly imported and thus can be intelligently targeted. Medical Device ASIA | November-December 2015 | 3


MEDICAL FAIR ASIA 2016 THE HALLMARK EVENT FOR ASIA’S MEDICAL AND HEALTHCARE SECTOR

COMING TO YOU SOON IN SINGAPORE 31 Aug – 2 Sep 2016 | Marina Bay Sands, Singapore

I

n just about nine months, Singapore will once again play host to MEDICAL FAIR ASIA, as it makes a much anticipated return from 31 August to 2 September 2016 to be held at a new venue – the Marina Bay Sands Singapore. The 11th instalment of the international exhibition on Hospital, Diagnostic, Pharmaceutical, Medical & Rehabilitation Equipment & Supplies continues its proud tradition of show-on-show growth, with an anticipated participation of 1,000 exhibitors from 45 countries, 20 national pavilion and country groups and an expected attendance of 15,000 qualified trade buyers and decision makers from across Asia, making it the largest MEDICAL FAIR ASIA trade event yet. Organized by Messe Düsseldorf Asia, MEDICAL FAIR ASIA is Southeast Asia’s most definitive event for the medical and healthcare industry, bringing together all facets of the industry for networking, sharing of best industry practices, as well as products, services and solutions development. Part of

MEDICA – World Forum for Medicine, a global series of medical events, MEDICAL FAIR ASIA’s contribution and growing relevance to the region and its associated industries is further underlined by the endorsement and continued support it receives from hospitals and medical associations all across Asia as well as from the Singapore Tourism Board and the Singapore Exhibition and Convention Bureau.

WHERE HEALTHCARE CONNECTS WITH TECHNOLOGY MEDICAL FAIR ASIA is well positioned to be the No.1 procurement stage for industry professionals to experience new and innovative technologies, solutions, products and services. At the 2016 edition, new disruptive digital healthcare solutions such as remote and wireless healthcare, IT platforms, wearable devices, smarter medicine and healthcare analytics are also expected to be showcased by participating exhibitors. Focused on equipment and supplies for the hospital, diagnostic,

4 | November-December 2015 | Medical Device ASIA

pharmaceutical, medical and rehabilitation sectors, the event continues to raise the overall capabilities and spur the growth of the region’s medical and healthcare sectors to meet the changing demands in both the public and private sectors, driving the next wave of healthcare modernization.

SYNERGISTIC CO-LOCATION WITH MEDICAL MANUFACTURING ASIA 2016 MEDICAL MANUFACTURING ASIA will return for its 3rd edition and run synergistically with MEDICAL FAIR ASIA 2016. Focused on the medical technology and medical manufacturing sector, the trade fair is jointly organized by Messe Düsseldorf Asia and the Singapore Precision Engineering & Technology Association (SPETA). The synergistic qualities of MEDICAL FAIR ASIA 2016 and MEDICAL MANUFACTURING ASIA 2016 bode well for exhibitors and visitors alike as they gain access to a diverse mix of high quality products and services.

ASIA - AT THE SPOTLIGHT FOR INVESTMENT, INNOVATION AND GROWTH IN HEALTHCARE The dynamic healthcare landscape across the Asia is riding on a strong growth momentum in areas of new entities, investments and products with the accelerated evolution driven by innovation and opportunities afforded by this region. As the medical and healthcare sector continues on the robust growth in Asia, MEDICAL FAIR ASIA will continue to be the preferred strategic business platform for region’s medical and healthcare industries. With exhibition spaces filling fast, interested exhibitors are encouraged to submit their space booking forms for MEDICAL FAIR ASIA 2016 at the earliest opportunity.

For more information on the trade fair, please visit : www.medicalfair-asia.com or medicalfar-asia@mda.com.sg


Hearing Regulatory Updates regarding Registration Requirements, Labeling Requirements and Collaboration in China, ASEAN, Japan, Korea and other Asia Pacific Countries Analyzing the Cooperation and Challenges for Market Access Strategy and Distribution of Medical Device in Asia Pacific Region Understanding Supplier Chain Management on Process and Products Changes and Security Management throughout Managing Requirements and Strategies in Clinical Trials across the Asia Pacific Region Managing Quality Regulatory Compliance for Medical Device Enterprises and GMP Standards in Different Jurisdictions Sharing Future Trends of Medical Device with Drug and Health Economics Situation Current Status and Background of Medical Equipment Leasing and M&A in Medical Device Market Exploring the Best Platform for Experience Sharing and Networking Opportunities with Industry Peers and Experts

Contact Us Ms. Vivi Ye Tel: +86 21 5258 8005 * 8106 E-Mail: vivi.ye@duxes.cn Web: www.duxes-events.com/mdap2/


“The sixth Hong Kong International Medical Devices and Supplies Fair (Medical Fair 2015) ended, having welcomed nearly 10,000 buyers over the three-day fair period, up 3.6 per cent year-on-year. Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Medical and Healthcare Device Industries Association, the fair saw encouraging growth in buyer attendance from Asia as well as strong interest in products targeting the silver market.”

International Medical Devices and Supplies Fair Ends NEARLY 10,000 BUYERS; STRONG DEMAND FOR ELDERLY CARE PRODUCTS wheelchairs and medical devices for elderly care and rehabilitation, from different countries. The CEO of the company, Jan Býma, said he had shortlisted five potential suppliers from the Chinese mainland, Taiwan and Korea. “Products that we are interested to source include: wheelchairs that help users stand up, foldable wheelchairs, walking aids as well as bathtubs and toilet seats for the elderly. Our initial orders are estimated at US$30,000 to US$50,000.” He said the fair showcased a broad range of products and was a good place for sourcing.

B

uyers from Japan, Taiwan, Singapore, and Vietnam recorded significant growth. It is an indication of Asia’s strong demand for medical supplies and services,” said HKTDC Deputy Executive Director Benjamin Chau. “An ageing population and increased health consciousness are also factors boosting the demand for healthcare equipment in the region. Silver Market According to the United Nations, it is estimated that there would be two billion people aged 60 or above by 2050, accounting for 21 per cent of the world’s total population. Reflecting this trend, many buyers attended the fair to source rehabilitation products and those targeting the silver market. Australia’s Comfort Mobility Pty Ltd. is a manufacturer of medical fixtures and supplier of healthcare equipment for the elderly. The company’s Director, 6 | November-December 2015 | Medical Device ASIA

John Minchenberg, said: “This is our first visit to the Medical Fair. We’ve found a potential supplier from Hong Kong for electrical wheelchairs. We will have further discussions with them on pricing and other details. If everything goes smoothly, we could see four to six containers worth of business a year.” First-time Czech buyer Meyra Cr s.r.o. is a producer of sports and electrical wheelchairs. The company also sources a range of traditional

Lin Chin Hsing, Manager of Taiwan’s Silver Care Health Management Consultants Ltd., was optimistic about business prospects for medical equipment and products for the elderly in Taiwan. He attended the fair to look for more product choices. “The HKTDC’s business matching service is very useful. I am already in contact with several Hong Kong and Chinese mainland suppliers for different products, such as a stair-climbing wheelchair, electrical wheelchair, and a pain-relieving device for women in labour. The visit has been very rewarding.” Boai Enterprise Group (China) operates nearly 100 hospitals and medical institutions offering general


and specialist services. Zhu Juhong, Assistant to the President of the Group, said the fair had helped them learn more about the latest technologies and products, and that initial contacts had been made with several potential suppliers from Hong Kong, Singapore and Canada. Product Launch The Medical Fair is an important platform for many manufacturers and suppliers to promote their latest medical technology and products to overseas buyers. The fair welcomed a record of more than 250 exhibitors from 11 countries and regions this year. ID Infinity Ltd. showcased its dental floss tool, Toothbat, as well as its latest WOW and Childers series. Director Gordon Lam said the response they received had exceeded earlier expectations. “A lot of buyers have expressed interest in our products; we have sold all 500 sets of products in less than two days. We are now taking pre-orders. Aside from Hong Kong buyers, we have also established ties with buyers from the Chinese mainland, Japan, Costa Rica, India, Korea, Thailand and Australia. Some of them even expressed interest in becoming our distributors.” Mr Lam said he would continue to exhibit at the Medical Fair to promote the brand and launch new products.

First-time exhibitor Active Fun Company Limited used the fair to introduce its trampoline which promotes exercise and mobility among the elderly. Product Manager Cyrille Guillot said the fair was useful for promoting the benefits of rebound therapy. “Buyers from different places have been very interested in our products. If we were to offer our products for sale, we would have sold over 100 units already. We will be discussing longterm cooperation with our new contacts.” Hong Kong Science and Technology Parks’ tenant Deltason Medical Limited showcased the Rex Bionics robotic device, which it distributed at the fair. The device uses advanced robotic technology to help spine cord injury (SCI) patients to stand up and walk around. Service Engineer Pete Witherspoon said: “The Medical Fair is an excellent trading platform for us to meet buyers from around the world and explore opportunities. We have promoted and demonstrated the robotic device at the fair and got a good response from many visitors. A Hong Kong buyer even offered to place an order immediately.” Regional Pavilions Foster Trading This year’s Medical Fair featured two

inaugural pavilions: the Canada Pavilion and the Taiwan Medical and Biotech Industry Association Pavilion. The Canada Pavilion comprised 11 companies, showcasing medical solutions and health management products and technology. Cynthia Carlone, Vice Consul & Trade Commissioner of the Consulate General of Canada in Hong Kong and Macau, said the fair offered a great chance for Canadian companies to explore the Hong Kong market and expand their presence in the Asia-Pacific region. “We have met many buyers on the first day, and we are optimistic that our companies will find the right trading partners here,” Ms Carlone said. Taiwan Medical and Biotech Industry Association’s Chief Secretary, Sidney Lin, said Taiwan’s medical industry has been expanding steadily over the years. The Association set up its inaugural fair pavilion to help its members develop their presence in the international market. “A number of buyers have expressed interest in our products. Several potential customers from the Chinese mainland and the UK have even examined some of our devices in depth, and we hope to develop business with them,” Mr Lin said. To help industry professionals gather market intelligence, the HKTDC organised a number of seminars during the fair, inviting industry experts to discuss topics such as the latest medical technology, regulations and market trends. The concurrent Hospital Authority Convention 2015, one of the region’s largest healthcare conferences, welcomed more than 5,000 healthcare professionals this year, and created strong synergy with the Medical Fair.  Medical Device ASIA | November-December 2015 | 7


Multiple Sclerosis Treatment Market Value to Reach $20 Billion by 2024

T

he value of the multiple sclerosis therapeutics market will rise slowly from $17.2 billion in 2014 to approximately $20 billion by 2024, at a Compound Annual Growth Rate (CAGR) of 1.5%, according to research and consulting firm GlobalData.“ “The company’s latest report* states that this growth, which will occur across the ten major markets of the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India, will primarily be driven by the continued uptake of premium products and an increase in treatment rates as a result of the availability of novel alternatives.“ “Thomas Parker, MPharmacol, GlobalData’s Analyst covering Neurology and Ophthalmology says: “The continued uptake of oral Disease Modifying Therapies (DMTs)

that typically have a higher annual cost of therapy and improved compliance rates, coupled with an increase of DMT treatment options that target progressive multiple sclerosis subtypes, will drive growth over the forecast period.“ However, the market is expected to plateau between 2018 and 2020, as the generic erosion of key branded products, such as Teva’s Copaxone and Novartis’ Gilenya, offsets the uptake of pipeline agents.” Despite this, the analyst notes that steady growth will resume from 2020 onwards, as additional pipeline products become available in Western countries.“ GlobalData’s report identifies eight late-stage drug products that are anticipated to enter the multiple sclerosis therapeutics market during

8 | November-December 2015 | Medical Device ASIA

the forecast period, with Roche/Genentech’s ocrelizumab, Celgene’s ozanimod, and AbbVie/Biogen’s Zinbryta expected to generate the highest revenues. Parker explains: “These efficacious pipeline products are expected to have a significant impact on the market, as they are likely to be popular with patients thanks to being oral formulations or requiring a less frequent dosage schedule. Collectively, GlobalData forecasts that the eight late-stage pipeline products will claim a 29.8% share of the global multiple sclerosis treatment market by 2024, generating combined sales of nearly $6 billion,” the analyst concludes.


21x28.indd 1

12/2/15 11:48 AM


The new set of dates for the

MEDICA and COMPAMED have been widely approved – the federal government shows its impressive presence

T

he health economy has exciting topics on its agenda: Digitalisation, networking and “wearables” create a dynamic effect The new set of dates running from Monday to Thursday has been widely accepted by the specialist visitors of the world’s largest medical trade fair, the MEDICA 2015, as well as the specialist supplier trade fair, COMPAMED 2015, being held in parallel. Both were well received right from the start this year. “The 19 trade fair halls were intensely visited without exception. The concentration of the MEDICA + COMPAMED during the normal working days of the week offers the specialist audience an even wider variety of travel planning options. This time, that had a positive effect on the well-visited trade fair forums

as well as the accompanying conferences. Here, the many programme highlights were very popular on all days,” said Joachim Schäfer, managing director of Messe Düsseldorf GmbH. From 16 – 19 November, 130,000 specialist visitors from around 120 nations came to Düsseldorf (previous year: 128,500). The portion of international visitors amounted to just over 50 percent, a strikingly large number came from the foreign markets of the USA, Latin America and especially from Iran and countries located in the Arabicspeaking regions. “The MEDICA is and shall remain a top event for decision-makers across all country borders,” Joachim Schäfer added with respect to the fact that 96 percent of the visitors have

10 | November-December 2015 | Medical Device ASIA

decision-making power. For the first time, the complete spectrum of innovations for out-patient and clinical care were offered by almost 5,000 exhibitors from 70 nations to experts from hospitals, practices, laboratories, the retail sector as well as from industrial ranks and cost bearers (insurance companies) that are especially relevant with regard to investments. The exhibitors especially benefit to a great extent from MEDICA’s high level of internationalisation on the side of visitors. This is because the medical industry is developing in a dynamic and unchanged manner, being particularly driven by the export business. For the coming year, the companies organised within the Federal Association of Medical Technology (BVMed e.V.)

expect an increase in sales of 6.8 percent on a worldwide level, whereas growth of 4.3 percent has been forecast for the German market. For the MEDICA 2015, the industry associations SPECTARIS and ZVEI have confirmed an evident growth of at least six percent for their member companies, also resulting from the “solid” growth levels of the business in Western Europe. In accordance with this, the sales volumes of German manufacturers is currently at around 27 billion euros at an export quota of 68 percent. Nevertheless, the German market, which is virtually just outside the gates of the MEDICA trade fair, will remain quite lucrative from an industrial perspective. Following the USA and trailing right behind Japan, it is considered the third largest market for medical technology and


medical products. Germany also scores top marks with its good healthcare infrastructure, a good level of care for patients, welleducated medical professionals and high standards regarding clinical research. Gröhe and Wanka provided for political momentum In order to guarantee this high level shown in a worldwide comparison in the future, not one, but two members from the ranks of the federal government used the MEDICA as premium platform for discussion and communication of current political issues. On the occasion of the opening of the MEDICA 2015, at the 38th German Hospital Conference, the Federal Minister of Health, Hermann Gröhe, underlined the significance of the planned hospital structure law to improve the financial resources of German hospitals. Following this, at the MEDICA ECON FORUM, he

discussed current health policy issues. On the occasion of the opening of the MEDICA 2015, the Federal Minister of Education and Research, Professor Johanna Wanka, presented, at the MEDICA HEALTH IT FORUM, the federal government's pioneering funding concept for medical informatics. It focuses on exactly what is still currently lacking in many cases: Many medical data are saved, scattered around hospitals, clinics or other medical institutions – often not even in digital form. Federal Minister Wanka highlighted that due to this, innovative IT solutions are in demand to provide for improved consolidation of data. “One of the largest subject-matter focuses of the MEDICA entails the digitalisation of the medical field. That is why the MEDICA 2015 is the ideal place to present the development concept of medical informatics. For us, it mainly concerns using medically relevant data for the well-being of patients. If these data are systematically

evaluated, more precise diagnoses and improved therapies can be derived therefrom as a result." The digital “revolution” could be based on patients The MEDICA visitors were able to be impressed with regard to numerous innovations presented by exhibitors in the face of the digital future already taking shape in very specific ways, but also by the lectures and presentations that were being held at the MEDICA CONNECTED HEALTHCARE FORUM (with the MEDICA App COMPETITION) or the MEDICA HEALTH IT FORUM. For this reason, among other things, projects and IT applications were presented providing a live connection to the patient, from the hospital bed into a classroom by means of the Internet, tablet PCs and a controllable robot or also the project entailing a telemedical consultation session to improve medical care in rural areas.

In particular, “wearables” and smartphones in combination with special health apps which can also be used by patients themselves have the potential of becoming an essential element of networked health in the future. The product innovations at the MEDICA 2015 included the first mobile 22-channel ECG system for tablet PCs and smartphones. The system not only makes the diagnosis of arrhythmias possible, but also the diagnosis of circulatory insufficiency (the early signs of a heart attack). A high level of interest was also shown for a mobile analysis tool to measure emotions for the optimum management of stress or a device similar to a Frisbee disc with a mobile telephone connection for the precise analysis of sleep activities – at a sleep laboratory level, but for uncomplicated use under the mattress in one's own bed. Everyone was also able to gain an impression at the “Wearable Technologies Show” (in hall 15) of

Medical Device ASIA | November-December 2015 | 11


“where the journey will go from here” and what analysis data patients will possibly be confronting their physicians with in the near future. The variety of devices ranges from lifestyle products, such as fitness trackers, to intelligent glasses and hearing devices, all the way to the latest trend – intelligent patches that continually retrieve physical data, but that can also administer medications in a minimally invasive manner. In general, the miniaturisation trend in the field of medical technology is continuing. This also applies with reference to devices and systems that should only really be used by “professionals in the field”. This includes, for example, extremely compact devices with sizes that are suitable for jacket pockets for medical imaging, whereby that can still be taken to extremes. This is because an ultrasound device was presented at the MEDICA 2015 consisting of a mere transducer having a connection to a tablet PC with a matching app. Also new: a system with a wireless transducer for particular freedom of movement during ultrasound examinations. Supporting programme is well received at an international level During the accompanying conferences, a subject of discussion was also made concerning how such medical technology innovations can bring about an optimum level of benefit within the scope of the daily routine at many medical institutions. In particular, these included the DiMiMED for military and disaster medicine, which also received good international participant feedback with its presentations held in English, as well as the MEDICA PHYSIO CONFERENCE conceived especially for physiotherapeutic treatment concepts. The MEDICA EDUCATION CONFERENCE, organised by the Germany Society for Internal Medicine (DGIM) and Messe Düsseldorf, offered many interdisciplinary and international programme highlights within the scope of 56 events with 168 speakers from Great Britain, the Netherlands, Sweden, Austria and

Poland, among others. The connection between science and medical technology was the common theme of the presentations. Thereby, with topics such as surgical robotics, gerontotechnologies, image fusion and interventional therapies, the select focuses of the four conference days ideally built a bridge to the innovations of the MEDICA exhibitors and were well received by the participants,” said the conference president, Professor Hendrik Lehnert, confirming the subject-matter focus in the concept of the continuing education event. Once again, the 38th German Hospital Conference, which was accompanied in a complimentary manner this time by the internationally oriented 3rd European Hospital Conference, was on the one hand dedicated to health policies according to the motto “Reform 2015 – conceived from the perspective of patients”. On the other however, “substantial issues” were also dealt with within the programme for approx. 1,900 participants from the field of hospital management. During the sessions of the IT initiative “ENTSCHEIDERFABRIK”, it was shown how company success can be increased by means of using IT. For example, a current hospital project that was presented is dedicated to process optimisation in emergency departments, which are considered to be cost-intensive – taking into consideration all relevant “interfaces” by means of improved communications and data exchange (e.g. between the A+E unit, the operating theatre and hospital bed planning). Suppliers as partners for the entire supply chain Being the leading trade fair for suppliers of the medical technology industry and being held for the first time during the course of four days, the COMPAMED took place in connection with the MEDICA already for the 24th time. A record number of 779 exhibitors presented technology solutions and services for the entire medical technology supply chain to the 18,800 specialist

12 | November-December 2015 | Medical Device ASIA

visitors in halls 8a and 8b – from the development to approval, all the way to mass production and sales, as well as spare parts handling. For example, the joint stand of the IVAM – the German Industry Association for Microtechnology – as well as both specialist forums integrated into the COMPAMED made the continuous miniaturisation a subject of discussion, entailing increasingly more compact and, at the same time, more complex systems. Highlights at the COMPAMED 2015 include, among other things, smart sensors for use in “wearables”, microsystem technology applications for intelligent implants or also printed electronics (made a topic of discussion in a session of the IVAM forum by the VTT Technical Research Centre of Finland). Dates of the next MEDICA and COMPAMED in Düsseldorf: 14 - 17 November 2016 Messe Düsseldorf GmbH Press and Public Relations MEDICA und COMPAMED 2015 Martin-Ulf Koch / Larissa Browa Tel. +49-(0)-211-45 60-444/-549 FAX +49-(0)-211-45 60-8548 E-mail. KochM@messe-duesseldorf.de


Air Liquide Medical Systems look far ahead after celebrating their 7th Make in India anniversary services facilities in more than 20 cities. Along with these manufacturing activities, ALMS also provides extensive services to its clients and maintains about 6,000 ventilators all over the country. ALMS has an efficient in house R&D department which specializes in hardware, software, medical design and plastics. About Business France:

Speakers, from left to right: Mr. Siva Kumar, Managing Director ALMS Pvt. Limited India, Jean-Marc Giner, ALMS Managing Director, Rohith Girish, Marketing Director, Air Liquide Medical Systems India

A

ir Liquide Medical Systems Pvt. Ltd. (ALMS), the medical equipment subsidiary of Air Liquide Healthcare, celebrated today, in the presence of the Ambassador of France in India, H.E. François Richier, their 7th year of manufacturing activities in India. On this occasion, ALMS unveiled their new Orion G ventilator, the first CE marked ventilator to be manufactured in India for both domestic and international markets. The launch of this new ventilator falls within Air Liquide Medical Systems (ALMS) strategy to bring hightechnology devices to the domestic Healthcare Sector. Orion G is indeed the latest of a complete range of 7 types of ventilators in India proposed by ALMS in India. Besides

ventilators, ALMS also manufactures CE marked Medical Air Compressors in India which are now exported to various countries.

worldwide” said Mr. Jean-Marc Giner, Managing Director of Air Liquide Medical Systems. About Air Liquide Group:

Orion G ventilator, developed with the support of ALMS teams in France will meet the requirements of ventilators in ICU, emergency and post-operative wards. It will feature color touch screen and battery backup. Orion G will be manufactured at the ISO 13485 certified ALMS plant in Chennai, Tamil Nadu, will be in conformity with the latest European norms. “We strongly believe in empowering our teams in India in order to develop our manufacturing and R&D activities also with the objective of exporting certified devices

Air Liquide Healthcare supplies medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients. In 2014, it served over 7,500 hospitals and 1,2 million patients at home throughout the world. The Group’s Healthcare business reached • 2,570 million in revenues in 2014, with the support of its 12,000 employees. Air Liquide Medical Systems Pvt Ltd is a company of the Air Liquide Group and has been present in India for the past 34 years with sales and

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the V.I.E international internship program. Founded on January 1, 2015 through a merger between UBIFRANCE and the Invest in France Agency, Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of publicand private-sector partners. For further information, please visit: http://en.businessfrance.fr

For further information, please contact: S. Sivakumar, Managing Director, Air Liquide Medical Systems PVT Ltd. Plot No.36, Annai Indira Nagar | Okkiyam Thoraipakkam | Chennai 600097| INDIA Tel: +91 (0) 44 4385 11 16/17 | Fax: +91 (0) 44 2458 00 43 | www.airliquidemedicalsystems.in

Medical Device ASIA | November-December 2015 | 13


Pharmaceutical Packaging Serialization 101

HOW MANUFACTURERS CAN MEET CONSUMER SAFETY REGULATIONS, PROTECT THEIR BRAND AND MAINTAIN PROFITS By Richard Nemesi, Global Vertical Manager for Pharmaceutical and Medical Devices at Videojet Technologies

C

ounterfeit products entering the supply chain is a serious problem that has long been plaguing the pharmaceutical industry. These drugs can contain ineffective or even harmful ingredients thereby posing a very dangerous threat to consumer safety. Additionally, counterfeit drugs cost the pharmaceutical industry billions of dollars each year in lost jobs and revenue, and can erode priceless commodities – brand reputation

and consumer trust. These safety concerns have given rise to various regional and global regulations requiring strict product serialization that allow products to be quickly and accurately traced throughout the supply chain (See: “Strict Rules & Regulations”). With that in mind, now is the time for pharmaceutical manufacturers to leverage coding and marking solutions within their packaging

14 | November-December 2015 | Medical Device ASIA

operations to help prevent counterfeiting.

efficiencies and protecting brand integrity.

In order to make the best choices possible, there are key factors to consider: performance and line integration. High-quality, permanent coding on a variety of packaging integrated into existing operations will allow pharmaceutical manufacturers to ensure regulatory compliance and consumer safety, while also maintaining manufacturing

Coding & Marking Solutions The mandatory information required on pharmaceutical packaging to be compliant with regulations represents a significant increase from current coding. Additionally, it is important to consider that the information must be both human and machine readable (See: “Strict Rules & Regulations”). While there is


a wide range of available coding and marking technologies, the good news is that recent advances have yielded state-of-the-art solutions to meet the challenges of the pharmaceutical industry, including Thermal Inkjet (TIJ), Laser, Print & Apply Labeling (LPA), Thermal Transfer Overprinter (TTO), and Continuous Inkjet (CIJ). TIJ is generally used to print traceability information including 2D DataMatrix codes – the standard code carrier for a wide range of regional and country-specific serialization requirements – onto packaging commonly found in pharmaceutical operations such as cartons, labels, blister foils, and pouches and barrier materials. The printer’s fire tiny ink drops through fine-gauge nozzles onto packaging as it passes a printhead or cartridge. This system is used for highresolution, ink-based, non-contact printing, utilizing heat and surface tension to move ink onto a package surface. Traditionally, TIJ was well-suited to printing high-quality text and bar codes on porous substrates, ensuring that complex and detailed codes are clearly readable for downstream verification. However, recent innovation in TIJ technology has made it possible to code on a range of non-porous substrates including films, foils, plastics and coated stocks. Laser marking can be used to print 2D bar codes as well as human readable codes. Laser is an ideal choice for creating permanent coding on pharmaceutical packaging such as cartons, bottles, labels, vials and ampules, tubes and blister

foils. Laser marking uses a beam of infrared light focused and steered with a series of carefully controlled small mirrors to create marks where the heat of the beam interacts with the packaging surface. TTO is good for marking flexible packaging such as pouches and barrier materials, offering high quality codes from date, lot, and time stamps to more complex codes such as bar codes, use warnings, and ingredients lists. TTO systems use a digitally controlled printhead to precisely melt ink from a ribbon directly onto flexible films, providing high-resolution, real-time prints. Extremely versatile, CIJ systems can be used to print on nearly any package type or product shape and is suited for a wide variety of packaging, including cartons, bottles, labels, vials and ampules, tubes, blister foils, pouches and barrier materials, and stick packs. CIJ technology is used for fluid-based, non-contact printing of up to five lines of text, linear and other 2D barcodes. Fast print speeds and a range of application-specific inks make CIJ a strong option for pharmaceutical packaging. To meet increased demand for high grade coding downstream on the packaging line, such as bundles and corrugate cases, Print and Apply Labelers (LPA) automatically prints and places labels of various sizes onto packaging. LPA can help pharmaceutical manufacturers ensure accurate label placement and high resolution coding. Substrates & Solutions Understanding the wide range of advanced coding and marking solutions is the first step towards

making an informed investment in coding and marking technology. Next, comes the critical part – pairing the right technology with the right application. Cartons/Carton Coding Cartons are one of the most common packaging formats used by pharmaceutical and medical products. Marking these cartons with high-quality human and machine readable codes is generally a critical element of any company’s traceability plan. TIJ is the most common choice for carton coding. It is typically advantaged in terms of throughput for dense coding applications, because speed is only governed by desired print resolution and the firing frequency of the resistors; the complexity of the code does not have an impact. Some vendors provide high-performance TIJ inks, which can further improve ink adhesion and contrast. Laser coding on cartons is another common selection, because of the simple and clean method of marking text, bar codes or images while using virtually no consumables. Laser creates permanent codes and can mark multiple adjacent products during indexing. Also good for cartons, CIJ codes adhere to nearly all common carton materials, including those with nonporous or water-resistant coatings. Bottles/Bottle Coding An extremely common pharmaceutical packaging format, bottles can be coded in numerous locations. For example, visible and ultraviolet (UV) or infrared (IR) visible marks can be

made to the side, bottom, label or cap of a bottle. CIJ printers work with a wide range of visible inks, UV- and IR-visible inks, and invisible inks for covert coding to aid brand protection. In addition, laser can be an effective method for creating indelible marks directly on the surface of a bottle or cap. Label Marking Marking directly on labels frequently requires integration with labeling equipment, which yields high quality, precisely positioned codes. TTO offers a simple method of direct contact coding on labels before application to the bottle or packaging. Seamless integration and robust bracketry are crucial. Capable of high resolution printing, TTO is ideal for bar codes, high content codes, and product information. For this application, the simple CIJ set-up includes integration of the small marking printhead and a flexible umbilical hose into labeling equipment. With a wide variety of inks, CIJ enables printing on both paper and plastic label stocks, offering color variety depending on desired contrast. TIJ is another ideal method for marking labels prior to application, allowing for high code quality and contrast while delivering complex 2D or DataMatrix codes. A small printhead integrates easily into label application equipment. Laser marking systems offer the capability to print crisp codes onto labels irrespective of original preprinted dark marked windows.

Medical Device ASIA | November-December 2015 | 15


Vial & Eye Dropper Marking Vial marking and eye dropper bottle marking is a challenging application due to the small surface size and reduced radius. This is best achieved with a coder integrated into the original equipment manufacturer (OEM) packaging that has been specifically designed for this type of package. CIJ is an effective marking technology for glass vials. Today’s CIJs use sophisticated software that can help ensure high drop placement accuracy, critical for small 2D codes. Autoclave resistant inks, as well as visible and UV inks can be used for brite stocking applications. CO2, fiber and UV lasers can also be used for the level of precision required for vial and eye dropper bottle marking. Fiber lasers can be utilized to mark on the vial crimping. Flexible Material Marking Blister lidding foils, Tyvek® and other barrier materials, pouches and a variety of flexible materials are used in packaging pharmaceutical and medical products. Coder integration in packaging systems is often needed for reliable, high quality coding of flexible packaging. Porous TIJ inks are optimal for printing on porous and semi-porous materials. Multiple printheads mounted in an array or integrated into a traversing system can be used for marking web-fed materials. Another viable choice for flexible material marking, TTO can be integrated into the web handling of packaging systems with bracketry specific to each packaging equipment OEM. TTO offers high resolution, wide format printing of alpha-numerics, bar codes, and simple one-color icons. In addition, laser marking can be used on a variety of blister lidding

materials. A properly integrated laser marking system can easily mark multiple lanes with high quality codes. Case Coding Effective supply chain management and traceability only works with highly accurate, clearly readable information on shipping cases. For case coding, the right solution depends on factors including supply chain partner requirements, and local standards and regulations. LPA is the standard way to identify product for delivery to supply chain partners. Automated labeling solutions can significantly reduce mislabeling as it is faster, more consistent, and has less potential for error than labeling by hand. TIJ is also used in high resolution printing directly onto cases. Its’ high resolution printhead can be stacked to create large images on the sides of cases and other porous substrates. In-line Integration The next step is knowing where and how to best implement serialization solutions. Coding solutions can be installed as components of broader

16 | November-December 2015 | Medical Device ASIA

packaging machines such as cartoners, starwheels, bottlers, and thermoformers, or they can be retrofitted into existing equipment. Incorporating coding solutions properly along the packaging line can go a long way in increasing the overall efficiency of a manufacturing operation. Cartoner Coding can take place in several locations within the equipment, integrated into the cartoner, itself, or on the outfeed conveyor. Keep in mind that printing can also take place upstream on the primary pack as required. Integrating the printer into a cartoner provides great product control and the additional benefit of applying the code after the product has been inserted into the carton. Sidegrip Conveyor The sidegrip conveyor can be used to mark visible and covert codes on the top or bottom of bottles. Downstream code verification can be easily accommodated while the bottle is engaged by the conveyor. There are distinct advantages to printing on the bottom of the bottle, an inherently more protected spot

which does not consume space that is visible when a product is on the shelf. Bottle Labeler Several different coding technologies can be utilized for contact or non-contact marking of the label before application. Precise label control can be used to facilitate high-quality alphanumeric and bar code printing. Vial/Ampule Starwheel When placing traceability codes onto small pharmaceutical packaging (less than 2 cm high) placement accuracy is key. The highly precise motion of the starwheel is ideal for this application. Code can also be printed on the top, bottom or side of vials and ampules, allowing for code density in a small space. Checkweigher The checkweigher’s unique performance properties such as precise material handling at high production speeds can be used to improve overall print and DataMatrix quality. Thermoformer A thermoformer applies and seals


thin-gauge plastic sheeting to protect a product, such as a pharmaceutical blister pack. Precise mechanical and controls integration make the thermoformer a strong choice for high quality marking on web-based materials, including blister lidding foils and other barrier films. Aside from the various points of integration along the packaging line, there are other factors to consider. Large pharmaceutical manufacturers utilize several different applications on separate lines (i.e. cartons, vials, bottles, etc.) requiring various packaging technologies. In addition, regional packaging preferences come into play. While the US prefers bottles, blister packs are popular globally. Additionally, once the right coding solution has been specified and integrated, it is time to focus on efficient and effective control. Centralized software management can be utilized that includes touch screen with interface and a common look and feel for ease-of-use. As counterfeit drugs continue to pose a growing problem for the pharmaceutical industry, regulations mandating the serialization of pharmaceutical products are on the rise. Pharmaceutical companies are under intense pressure to comply with coding and marking requirements designed to increase traceability throughout the supply chain. The ultimate goal of total transparency between all supply chain partners will ensure product authenticity, protecting consumer safety and – as a by-product – brand reputation. However, beyond mandatory compliance, pharmaceutical companies have financial-based considerations that cannot be ignored. Manufacturing efficiencies must remain high in order to maintain the bottom line. To help ensure the best coding and marking solutions possible, manufacturers need a firm grasp on the wide range of technologies, based on coding needs (i.e. 2D, DataMatrix, etc.), as well as packaging types and substrates. For the highest level of efficiency, the solutions must then be properly integrated into existing operations. While it might seem like

a daunting task, experienced providers are prepared to help you understand how the puzzle fits together, ensuring product authenticity, regulatory compliance, and overall operational efficiency. SIDE BAR Strict Rules & Regulations In the US, the Drug Supply Chain Security Act (DSCSA) was signed into law November 2013 setting new federally mandated requirements for traceability of pharmaceutical products throughout the drug supply chain. The initial phase of this multi-faceted act began January 2015, requiring manufacturers, wholesalers, and re-packagers to share batch-level information, including transaction information (TI), transaction history (TH), and transaction statements (TS) as drugs move along the supply chain. For phase one, paper documentation will be sufficient in order to meet requirements for compliance. This vital information will be conveyed to the pharmacy level, ensuring quick and accurate product authenticity verification, also allowing for the immediate quarantine or investigation of a suspect product Moving into phase two, by November of 2017, product information will be required on drug product packaging for serialization, marking pharmaceutical products with a unique product identifier that

includes its National Drug Code (NDC) or Global Trade Identification Number (GTIN), unique to the product, based on chemical composition and does not change unless the product is reformulated. Additional required information includes serial number, lot number and expiration date. This information must be easily readable by both machines and people. Finally, by 2023, the third phase will feature complete interconnectivity, meaning shared ownership of data between all supply chain partners, allowing for full traceability of pharmaceutical products back to their origin. This concept is known as “cradle to grave” traceability. Not limited to pharmaceutical products, these serialization requirements include medical devices, as well. In 2013, the Federal Drug Administration (FDA) passed legislation mandating that mandates a Unique Device Identification (UDI) code on most medical devices in the US. About the Author: Richard Nemesi is Global Vertical Marketing Manager for Pharmaceutical and Medical Devices at Videojet Technologies. His main responsibilities at the company are to develop a deep understanding of global trends and customers’ needs within the sector, create marketing content to support sales efforts and provide

counsel to product development teams on equipment functionality. Prior to Videojet, he was a Systems Sales Specialist in the Systems and Technology Group at IBM. About Videojet Technologies: Videojet Technologies is a worldleader in the product identification market, providing in-line printing, coding, and marking products, application specific fluids, and product life cycle services. Our goal is to partner with our customers in the consumer packaged goods, pharmaceutical, and industrial goods industries to improve their productivity, to protect and grow their brands, and to stay ahead of industry trends and regulations. With our customer application experts and technology leadership in continuous inkjet (CIJ), thermal inkjet (TIJ), laser marking, thermal transfer overprinting (TTO), case coding and labeling, and wide array printing, Videojet has more than 325,000 printers installed worldwide. Our customers rely on Videojet products to print on over ten billion products daily. Customer sales, application, service, and training support is provided by direct operations with over 3,000 team members in 26 countries worldwide. In addition, the Videojet distribution network includes more than 400 distributors and OEMs, serving 135 countries.

Medical Device ASIA | November-December 2015 | 17


18 | November-December 2015 | Medical Device ASIA


Medical Device ASIA | November-December 2015 | 19


Sharp’s Revolutionary Air Purifiers Helps Prevent Airborne Diseases

P

rithvi, Akash, Jal, Agni and Vayu – These are the five elements that we are made up of. Prithvi (Earth) and Akash (Sky) are beyond our control, Jal (Water) & Agni (Fire) are already taken care of in best possible ways. What about Vayu (AIR)? Air is the most important substance going into our body from outside. During the developing years (0 to 13 years) of a child, the impurities in AIR are ignored by most, causing the biggest damage to our health with several AIR BORNE DISEASES. The homes that we build today, in-spite of our perceived best architectural designs, we fail to comply with this basic need.

causing germs and irritants. “Several health authorities have recognized that certain types of air purifiers are beneficial in reducing the amount of Particulate Matter 2.5 in the room. During my studies of all Air Purification techniques, I have observed that the Sharp Air Purifier equipped with Plasmacluster Ion Technology is much superior in terms of performance, reliability and certifications. Proper ventilation and allowing direct

Sharp’s revolutionary air purifier enabled with its Plasma Cluster Ion Technology could be a real saviour. It creates forest fresh air by generating the same level of Positive & Negative Ions found in natural environments like forest, resorts, parks which in the process create Hydroxyl Radical (called Nature’s Detergent) thus killing harmful substances not only from the air but also from the surface and eliminates bad odour. Unlike other Air Purifiers, employing passive method that requires the air to pass through a set of filters to clean and recycle the air, Sharp comes with an Air Purification System as it incorporates an active method that reduces suffocation/ staleness by generating fresh air. Plasma cluster Ion Technology Mimics Nature by generating Positive and Negative Ions which are released into the air then reaches out to the surface and the corners of the room destroying infection 20 | November-December 2015 | Medical Device ASIA

sunlight in interior spaces are equally important steps towards improving air quality.” said Dr Rajarshi Bhattacharyya, National Head of The Times Foundation. Imagine a Petrol Engine running on a mixture of Petrol and Kerosene! If we breathe AIR and POLLUTANTS together, our Immune System is challenged, gets tired and the performance gets affected. We easily take Doctors’ assistance, who prescribes several expensive and harmful antibiotics to fight the common flu etc, if we rethink and use PREVENTION than CURE for airborne diseases, we might look forward to be a healthy nation. Breathing fresh air for at least 8 to 10 hours a day, will nourish the cardiovascular system and rest the Immune System thus giving the stamina and energy to fight diseases while in challenging environments.



Rigel SafeTest 60

New Rigel Safetest 60 Provides Fast And Effective Testing Of General Purpose Medical Equipment infusion pumps, CPAP’s, centrifuges and other similar equipment that does not require patient lead testing. As such, the SafeTest 60 is suitable for electrical testing to ensure compliance with a range of international safety standards including leakage testing to IEC 60601, IEC 62353, IEC 61010 and NFPA-99. In addition, to meet the needs of some specific types of equipment, the unit also has the capability to carry out insulation testing in line with IEC 62353 and accurate high current, low energy earth bond testing to both IEC 62353 and IEC 61010.

Rigel has introduced a new handheld safety analyser for the routine electrical testing of basic medical and laboratory equipment.

In all cases, full manual control means only those specific tests that are required can be carried out, with minimised power breaks and full control of power cycles helping to ensure that testing is carried out quickly and efficiently – without any compromise in accuracy or integrity of testing.

he new Rigel SafeTest 60 is a compact, robust and reliable safety analyser that is particularly well suited to high volume testing demands, with a simple colour coded user interface, push button operation and the fast step-through of test routines.

As part of the new streamlined approach to carrying out electrical safety tests, an automatic warning of secondary earth/ground paths ensures that users are made aware prior to invalid results being obtained, eliminating time consuming re-tests and ensuring correct and valid results are provided first time.

The general purpose tester includes a comprehensive range of safety tests for hospital and medical equipment such as medical beds and chairs, operating tables, hoists,

The new Rigel SafeTest 60 is available in a wide range of power supply configurations to meet standard local operating conditions around the world.

T

22 | November-December 2015 | Medical Device ASIA

The new SafeTest 60 forms part of a comprehensive range of high performance specialist biomedical test equipment from Rigel Medical. Full details at www.rigelmedical. com/safetest60. Biomedical Test Equipment from Rigel Medical With over three decades of experience, Rigel Medical manufactures a comprehensive range of advance technology Biomedical test equipment, including a dedicated range of Electrical Safety Analysers, all-in-one Vital Signs Simulator, NIBP Simulator, SPO2 Simulator, ECG Simulator, Defibrillator Analysers and Ventilator Testers. Rigel Medical was the first company to produce a dedicated electrical safety analyser to meet the IEC601 requirements and has since expanded its product offering to a complete range of biomedical test equipment. As an established and respected producer of safety analysers, our products offer the latest technologies such as incorporating Bluetooth and RFID capability, whilst our latest medical safety analyser is using a new test method to accurately measure earth / ground bond resistance at lower currents. Our biomedical test equipment which includes; safety analysers, function testers and vital signs simulators help biomeds (BMETS), medical physics staff, biomedical and service engineers to comply with strict regulatory guidelines for medical electronic equipment, designed to meet IEC 60601 and the newly published standard IEC62353.


SEKO LOGISTICS’ EUROPEAN AND U.S. MEDTEC OPERATIONS AWARDED ISO 13485 backward,““constantly moving) “• Pick-up, delivery, set-up, installation, de-installation services “• Trained & certified delivery personnel “• Customized Standard Operation Procedures “• Post event surveys/ questions “• Technical/Power-up services “• Managed network of specialized providers““MedTec Value-Added Hub Services include: “• Decontamination “• Service/ Repair “• Kitting/Replenishment “• Quality & compliance records (patient data) “• Contract Mfg “• Crate design / production““About SEKO Logistics “We provide a suite of logistics services which enable you to use your supply chain as a competitive differentiator. As a customer centric organization, we are powered by the expertise of our people and our in-house-developed, best in class, customizable technology.

C

ERTIFICATION““SEKO Logistics’ European MedTec control tower has been awarded ISO 13485 certification, the foundation for manufacturers to address medical device directives, regulations and responsibilities.““ISO 13485 is the known and trusted quality standard in the medical device industry and is adopted by authorities, suppliers and manufacturers around the world to demonstrate their commitment to protecting the safety and integrity of medical devices.““SEKO MedTec is one of SEKO Logistics’ biggest and fastest-growing businesses and provides highly specialized solutions focused exclusively on the medical device industry. This includes dedicated program

management for demonstration equipment, finished goods and returns, as well as contract logistics and fulfillment services. SEKO’s engineering, transportation and software services for the industry are backed up by control towers, knowledgeable staff, and dedicated clean rooms and facilities.““In the U.S., SEKO has also achieved ISO 13485 certification at its U.S. MedTec control tower located in State College, PA as well as for its MedTec warehouses and hubs in Costa Mesa, CA, Pittsburgh and Baltimore.““Robert Shearer, Managing Director of SEKO MedTec, said: “Quality and compliance underpins everything that happens in the medical device sector and this certification is an extension of SEKO

Logistics’ specialization in this important and strictly-regulated industry. We continue to innovate with sophisticated integrated logistics solutions and software for the medical industry. Gaining ISO 13485 certification for our EU MedTec operation, coupled with full certification of all of our U.S. MedTec sites provides our current and potential clients with the knowledge that their products are handled to the highest standards across both continents. About SEKO MedTec““SEKO MedTec Field Services include:““• Deliveries (forward), Returns (backward), Demos (forward &

It is this combination which gives SEKO its strength. With over 120 offices in 40 countries worldwide, SEKO’s unique shareholder management model enables you to benefit from our specific industry sector expertise, coupled with vital in-country knowledge and unparalleled service at the local level. This unique model provides you with:• Hands-on service and support “• Personal relationships “• Creative, customized solutions “• Responsiveness and reliability “• Flexibility and consistence““We have a flat management structure, with just three layers between you and the CEO, making us ‘fast on our feet’ in delivering solutions that can meet your exact requirements. This lean and nimble structure increases our decision-making speed and gives us an ability to implement customized solutions which far exceed those of our competitors. For more information visit our website www.sekologistics.com

Medical Device ASIA | November-December 2015 | 23


Sugar disease growing at alarming rate in India 51 % WOMEN & 60 % OF MEN IN THE AGE GROUP OF 20-80 YEARS ARE WORST AFFECTED

M

The in-depth analysis revealed that over 60% of all samples from male and 51% of samples from female were diabetic. In addition, over 28% of the samples analysed from children between the age group 012 was found to be diabetic.

Commenting on the study Dr. Sonali Kolte, General Manager, Medico Marketing said, “India is already infamous as the diabetic capital of the world and the incidence is increasing due to various factors, such as unhealthy eating habits, lack of physical activity, family history and stress. Diabetes is a lifelong condition and requires regular monitoring. People with diabetes are susceptible to kidney dysfunction, cardiovascular diseases, neurological problems and much more. Hence Diabetics need to undergo regular tests and monitoring to

AGE GROUP / CATEGORY

DIABETIC

TOTAL SAMPLE SIZE

0-12 (Juvenile ) Male (20 -80 & Above) Female (20 -80 & Above)

1333 4810 304736 506047 262986 510495

etropolis Healthcare – the pathology specialists and multinational chain of diagnostic centres conducted a comprehensive analysis of over 10,21,352 samples that were processed for fasting blood sugar for over the last three years.

24 | November-December 2015 | Medical Device ASIA

PERCENTAGE

28% 60% 51%

ensure that all their vital parameters are normal’’ According to statistics from International Diabetes Federation, India Chapter around 65.1 million people are affected with diabetes compared to 50.8 million in 2010. It is expected to reach around 69.9 million by 2025. There are three types of diabetes: 1 Type 1 Diabetes - The body does not produce insulin. Approximately 10% of all diabetes cases are type 1. A healthy eating plan, adequate exercise, and insulin intake can lead a normal life. 2. Type 2 Diabetes -In type 2 diabetes your body does not use insulin properly. This is called insulin resistance. At first, your pancreas makes extra insulin to make up for it.

But, over time it isn't able to keep up and can't make enough insulin to keep your blood glucose at normal levels. Approximately 90% of all cases of diabetes worldwide are of this type. It often results from excess body weight and physical inactivity. Healthy diet, regular physical activity, maintaining a normal body weight and avoiding tobacco use can prevent or delay the onset of type 2 diabetes. 3. Gestational Diabetes - This type affects females during pregnancy,usually around the 24th week – many women develop gestational diabetes. A diagnosis of gestational diabetes doesn't mean that you had diabetes before you conceived, or that you will have diabetes after giving birth. When you have gestational diabetes, your pancreas works overtime to


produce insulin, but the insulin does not lower your blood glucose levels. Although insulin does not cross the placenta, glucose and other nutrients do. So extra blood glucose goes through the placenta, giving the baby high blood glucose levels. This causes the baby's pancreas to make extra insulin to get rid of the blood glucose. Since the baby is getting more energy than it needs to grow and develop, the extra energy is stored as fat. This can lead to macrosomia, or a "fat" baby. Babies with macrosomia face health problems of their own, including damage to their shoulders during birth. With type 1 diabetes, the symptoms usually happen quickly, in a matter of days or a few weeks. They're much more severe, too. The most common diabetes symptoms include frequent urination, intense thirst and hunger, weight gain, unusual weight loss, fatigue, cuts and bruises that do not heal male sexual dysfunction, numbness and tingling in hands and feet. It is advisable to get your blood & urine checks done immediately, if you suffer from any of the above symptoms. Treatment for all types of diabetes is available. Diabetes type 1 lasts a lifetime, there is no known cure. Type 2 usually lasts a lifetime; however, some people have managed to get rid of their symptoms without medication, through a combination of exercise, diet and body weight control. If diabetes is not adequately controlled the patient has a significantly higher risk of developing complications related to cardiovascular diseases, neurological problems and many more. Being overweight, physically inactive and eating the wrong foods all contribute to the risk of developing type 2 diabetes. If you are overweight or obese, you are at greater risk of developing type 2 diabetes,alterations of hormones such as leptin, cortisol, adiponectin involved in food intake can lead to obesity. It is important to check

these hormones if you are obese or overweight. Obesity appears to spreading across India in part at least as a result of processed Western food. India’s economic boom has been accompanied by a meteoric increase in the number of people with diabetes. Even if the prevalence of obesity remains stable until 2030, which seems unlikely, it is anticipated that the number of people with diabetes will more than double as a consequence of population aging and urbanization. In association with increasing diabetes prevalence, mortality will inevitably result in increasing proportions of deaths from cardiovascular disease, as well as increased prevalence and associated consequences of other complications of diabetes. A concerted initiative is required to address the diabetes epidemic.

About Metropolis At Metropolis, what we believe is what we say and what we say is what we do. Being empathetic to our customers and being committed to their needs is in our DNA. Metropolis has grown to harness a culture that is open, synergistic, progressive and scientific in nature. We are the Pathology Specialists delivering over 30 million tests a year, catering to more than 20,000 Laboratories, Hospitals, Nursing homes and 2,00,000 doctors. With 34 years of experience in delivering accurate reports, Metropolis has earned the reputation of being India's most respected and only multinational chain of diagnostic centres with presence in UAE, Sri Lanka, South Africa, Kenya, Mauritius and Ghana. Driven to make a difference, our wide network includes 130 state-ofart Laboratories with over 1000 collection centres, processing over 4500 varieties of tests and supported by an efficient team of more than 3500 people. Equipped with cutting edge technology, innovative work equipment, expansive logistics network and rigorous processes, Metropolis ensures and delivers precision and accuracy in every

single test; each time, every time. Over the past two decades, Metropolis has expanded into new service lines like Clinical Trials, Hospital Lab Management, Home Health Services, Preventive Health Check-ups and Corporate & Wellness Solutions. Metropolis is at the forefront in adopting cutting edge technologies and services that contribute new revenue streams and has positioned the company on the pedestal it is today. Today, we are one of the few laboratories that has received the CAP (College of American Pathologists), accreditation, the global gold standard in Laboratory Accreditation. We have also received the NABL Accreditation (National Accreditation Board for testing and Calibration Laboratories). In addition, we also adhere to CLIA (Clinical Laboratory Improvement Amendments) program and follow the guidelines laid by GCLP. Our unit in South Africa is accredited by SANAS (South African National Accreditation System is the only accreditation body approved by South African Government). At Metropolis, we believe in unveiling the inner health of individuals and this motto extends to our corporate social responsibility activities as well. Giving back to the society is embedded in the value system of Metropolis and we believe and aim to bring about a positive change in the nation. Metropolis has been at the forefront in conducting impactful camps and driving numerous workshops for different sections of the society for the past 3 decades. We partner with societies, corporates, educational institutions, government bodies, NGOs, wellness foundations and a host of other organisations to make a difference to the lives we touch. Our camps and awareness workshops emphasize on preventive healthcare and early screening of diseases. Some of our most recent associations include Epilepsy Foundation, Hep Free India, Mumbai Traffic Police, Kishori Foundation, Children of Blind School and JeevanJyot Cancer Trust.

Metropolis has been awarded numerous accolades like the ‘Best Diagnostic Company of the year’ by Modern Medicare in 2006 and ‘Best Diagnostic Company of the Year’ in 2010 by Frost & Sullivan. Metropolis was also bestowed with ‘Best IT Integration in Customer Service Management’ at the e-Health World Expo 2011. Metropolis was also honoured with the ‘Quality Brand Award’ by NEHRDO in 2012. Metropolis won the ‘CMO Asia Award’ for Best IT practices in Healthcare in 2012. Metropolis recently bagged the ‘India’s most promising brand award’ at Global Indian Excellence Summit 2014 held in London. Metropolis also won the acclaimed Emerging Companies Excellence Award hosted by Business Today in 2014. In 2015 Metropolis won the Best Diagnostic Company Award at the National Awards for Excellence in Healthcare hosted by CMO Asia. Metropolis also won the Best Diagnostic Service Provider Award hosted by VC Circle. Metropolis Healthcare is led by Ameera Shah, Promoter, Managing Director & CEO. An International & National award winner, Ms. Shah was conferred with ‘The Young entrepreneur of the Year Award’ by GE in 2006 and ‘The Young Achiever of the Year Award’ at the CMO Asia Awards in 2011. She was also the recipient of the prestigious ‘Young Entrepreneur of the Year Award’ in 2011 organized by Entrepreneur India and Bloomberg. She has been honored with ‘Exemplary Women Leadership award’ at the World Women Leadership and Congress awards 2014. She has been chosen as one of the most respected leaders under 40 years by Economic Times & Spencer Stuart (2014). Recently Forbes Asia listed Ms. Shah in the Asia’s Most Powerful Women 2015 for powering the rise of Metropolis Healthcare and brining a significant shift in the diagnostics industry. Ms Shah has also been featured in the acclaimed ‘Young Global Leader’ list brought out by the prestigious ‘World Economic Forum’ in 2015.

Medical Device ASIA | November-December 2015 | 25


POULTRY INDIA’S PROTEIN AWARENESS CAMPAIGN REACHES TELANGANA; HIGHLIGHTS PROTEIN DEFICIENCY IN THE COUNTRY

 INDIA HOUSES 194.6 MILLION PROTEIN DEFICIENT AND UNDERNOURISHED PEOPLE - THE HIGHEST IN THE WORLD - AND WHERE MORE THAN 65 MILLION CHILDREN UNDER THE AGE OF 5 ARE STUNTED  AN AVERAGE INDIAN CONSUMES APPROX 37 GMS/DAY, WHICH IS NEARLY HALF THE LEVELS RECOMMENDED BY WHO  A PERSON MUST CONSUME AT LEAST 1 GM OF PROTEIN PER KILOGRAM OF BODYWEIGHT PER DAY

I

ndia's poultry industry is one of the largest in the world and employs over 25 million people. It contributes Rs. 95,000 crores to the economy each year with Telangana contributing substantially to the figure Poultry India, an advisory body with a unanimous primary mandate of spearheading the ‘Eat Right, Eat Healthy’ educational campaign, today said its all-India Protein Awareness Campaign has picked substantial momentum following its launch in Pune last month with nutritionists and poultry farmers

assisting in propagating the message through various mediums. The national initiative to educate people on the vital role proteins play in enhancing day-to-day health, fitness and general wellbeing includes an eclectic choice of communication vehicles like roadshows, open house discussion with parents, teachers and school children in urban and semi-urban areas, town-hall meets with village elders and guardians, etc. Poultry India has also begun circulate printed material to retail outlets highlighting the importance of

26 | November-December 2015 | Medical Device ASIA

protein and what would be the consequences for the lack of its intake.

economy each year with Telangana contributing substantially to that figure.

It is but natural that the state of Telangana,which is among the country’s largest poultry producers, is the next stop on this campaign. Chief Minister K Chandrasekhar Rao has recognised poultry as a key sector and has extended help to its farmers through subsidies and increased facilities.India is the third largest egg producer in the world after China and USA and employs over 25 million people. It contributes Rs. 95,000 crores to the

One out of every five eggs produced in India is from Telangana and Andhra Pradesh.Little wonder then that the Government of India closely worked with Poultry India and its associates to propagate World Egg Day on 9th October, 2015 through several events including essay writing and egg recipe/ cooking competitions for students, women, teachers, as also created awareness on the importance of eggs by distributing flyers


and information brochures. Commenting at the launch Mr. Harish Garware, Executive Committee member, Poultry India, said, “Despite improvement in education levels and poverty elevation India unfortunately is still a malnourished, protein deficient nation and world capital of TB, diabetes and obesity. This is only because our food culture has not yet evolved with times. We do not dispute the importance of protein but none of us are aware how much we need daily and how to fulfill it. We need one gram of protein for every kilogram of our body weight everyday because our body cannot store protein. This is the message Poultry India wants to take forward this in this Protein Awareness campaign for the benefit of all. Prosperity automatically brings in awareness and a shift in our nutritional culture. If you keenly observe, all prosperous countries have eventually shifted from carbohydrate-based to healthy protein rich food culture.” According to a definitive survey 'Protein Consumption in the Diet of adult Indians Survey' (PRODIGY) published in India highlighted the fact that 80% of all Indians are protein deficient. The survey was conducted in seven major Indian cities among 1,260 respondents and concluded that and as many as 91% vegetarians and 85% nonvegetarians are deficient in proteins.. The epidemic of lifestyle diseases obesity, diabetes hypertension, and high triglyceride levels - in urban India can also be addressed if Indians increase their dietary protein intake, the survey said. (Ref: http:// www.hindustantimes.com/wellness/ 80-of-indians-suffer-from-proteindeficiency/article1-1354357.aspx

Mr. OP Singh, Core Committee Member, Poultry India said,“Protein cannot be stored. Your body needs it daily. In right quantities.Today, Protein-Energy malnutrition (PEM) in young children is currently the most important nutritional problem that has reached near epidemic status. This often results from consuming food that is low in protein. Through our efforts we are aiming to significantly reduce our nation’s malnutrition and protein deficiency quotient with cost effective and economical source of Proteins which, most importantly, is easily available anywhere in any street corner outlet.”

you that our Chief Minister Mr. K Chandrashekar Rao has taken measures to ease the burden on the State’s farmers with subsidies on feeds and electricity as also accrediting the poultry industry with an Agriculture Status. This is giving us confidence that our government is backing us in everything we do, especially in the Protein Awareness Campaign The ‘Eat healthy, Eat Right’ campaign is thus aimed at educating people on the goodness of proteins -- from any source vegetarian or non vegetarian and the important role proteins play in supporting day-to-day health, fitness and general wellbeing.”

International Diabetes Federation (IDF) official estimate of India’s diabetic population was 65.1 million. Indian media reported around 67 million diabetics in India in November 2013. That’s dangerously close to IDF’s 2007 prediction of India’s diabetic population in 2025 touching 69.9 million. It seems we are reaching this unsavoury milestone 10 years too early!

“Our Honourable Prime Minister NarendraModilauncheda worthy campaign Swacch Bharat-Swasst Bharat to educate us on how to stay clean and thus stay healthy. Poultry India wants to support our PM by educating people on eating right, eating healthy. We want to tell them that obesity means various life threatening diseases and that it decreases the quality of life and increases individual and national healthcare costs,” Mr. Ranjith Reddycontinued.

By 2030, India will be home to 1.6 billion people, which means overall demand for food will be much higher. Furthermore, while there are many poor in India (roughly 60% of the population), there are also some very rich people, along with a rapidly rising middle class population. Incomes have been rising by 7-8%. Hence there is greater demand not just for more food, but also for better quality food. Mr. Ranjith Reddy, Managing Director of SR Hatcheries and head of Poultry Breeders Association of Telangana said, “The Protein Awareness Campaign is a worthy project by Poultry India and we applaud it wholeheartedly. I also want to tell

Another key highlight of the campaign is highlighting the various sources of proteins in easily available daily foods. Dal and beans offer protein and tend to be sources of several minerals like potassium and magnesium. On the downside, they offer only a moderate, at best, amount of protein. Digesting dal and beans is not easy, hence many experts recommend limiting its intake quantity for up to 50-60 grams per day. However, this gives you only 10-11

grams of protein per day which is much less than the recommended daily protein intake of 1 gram of protein for every kilogram of bodyweight everyday! So if you weigh 70kgs, you need 70gms of proteins everyday! Indian diets derive almost 60% of their protein from cereals with relatively low digestibility and quality. There have been several surveys of diets and protein intakes in India by the National Nutrition Monitoring Board (NNMB) over the last 25 years in urban and rural, as well as in slum and tribal populations. Data of disadvantaged populations from slums, tribals and sedentary rural Indian populations show that protein intake (mainly from cereals) is about 1 gm/kg/day. However, the protein intake looks less promising in terms of the protein digestibility corrected amino acid score (PDCAAS), using lysine as the first limiting amino acid, where all populations, particularly rural and tribal, appear to have an inadequate quality to their protein intake. The quality of egg and chicken protein is complete with all required amino acids for effective utilisation by the body with PDCAAS scores of 1. If one were to get protein needs from dal alone you would have to consume a huge amount of dal and beans. (See below chart) They contain 25% protein and approx 50% starch or high carbohydrate content, which explains why they’re so hard to digest. Also, beans are rich in protein and starch (requiring different digestive environments and enzymes) and this can make thorough digestion more difficult. While its protein is being digested, starch lies in the stomach and ferments producing gas and toxins making one feel bloated and

Medical Device ASIA | November-December 2015 | 27


uneasy.Eggs contain decent amounts of vitamin A, D, E, K, B5, B6, B12, B2 calcium, phosphorus, folate, selenium and zinc. They are highly fulfilling and tend to make eat fewer calories, helping in losing weight. Dr Janaki Srinath, Nationally Acclaimed Nutritionist from Hyderabad said: “Given the risk low protein levels pose to the health of Indians, spreading proteins evenly across meals is extremely important. Combining vegetable, grain, pulses, egg and dairy products gives you a perfect protein intake for the day. “Consumption of adequate protein ensures strong immune defense, efficient signaling of nerves and impulses, healthy hair and mainte-

nance of fluid balance in the body. Protein can also turn into an energy provider when required by the body. Insufficiency of protein in the body affects all organs and overall growth and development. Probably the most important contribution of protein is its ability to reduce appetite and cause a spontaneous reduction in calorie intake. Protein intake is essential for stages of life leading to a better body composition and metabolic rate in modern sedentary lifestyles. Protein is much more satiating than both fat and carbs”, Dr Janaki added. Mr D Ram Reddy CMD, Sneha Farms Ltd said, “I am so glad the awareness through Poultry India’s Protein

BELOW IS A TABLE OF PROTEIN CONTENT FOR VARIOUS FOODS: Item Weight in gms per 100gms (Rs approx.) Egg Chicken Mutton Milk (FULL FAT) Yogurt Paneer (FULL FAT) Fish Urad Dal Moong Dal Tur Dal

Protein per 100gms

100 (2 eggs) 100 100 100 100 100 100 100 100 100

13.2 30 26 3.2 5 11 22 24 24.5 22

28 | November-December 2015 | Medical Device ASIA

Commodity price 9 15 40 5 13 35 30 16 16 16

campaign is growing strong. We, the poultry farmers of Telangana, appreciate this campaign and also thank our state government for not only supporting the campaign but also thank our Chief Minister for his help to the poultry sector.” WHAT IS PROTEIN Proteins are a group of biological compounds which are present in every live cell, organ and tissue of the body. They are there in the form of enzymes, antibodies, hormones and much more. Meaning ‘first’ or ‘of prime importance’ in Greek, proteins participate in every cellular process occurring in the body. Proteins are responsible for the formation, regulation, repair and protection of the body of each organism. It executes a range of functions within living beings including catalysis of enzymes, DNA replication communication and coordination within the cells, molecular transportation from one location to another. There are 20 amino acids considered essential because the body must have all of them in right amounts to function properly. Twelve of these proteins are manufactured in the body but the other eight amino acids must be

provided by diet. Foods from animals sources such as milk or eggs often contain all these essential amino acids, while a variety of plant products must be taken together to provide the body and the mind all these necessary proteins. Good healthy sources of proteins are not hard to find for both vegetarians and non-vegetarians. Meat eaters can choose from eggs, chicken, cooked lean meat and fish. Vegetarians can choose from nuts, seeds, soy products like tofu, dairy products and legumes including variety of beans and split peas. Key facts (World Health Organisation) Worldwide obesity has nearly doubled since 1980 In 2008, more than 1.4 billion adults, 20 and older, were overweight. Of these over 200 million men and nearly 300 million women were obese 35% of adults aged 20 and over were overweight in 2008, and 11% were obese 65% of the world's population lives in countries where overweight and obesity kills more people than underweight More than 40 million children under the age of 5 were overweight


or obese in 2012 Obesity is preventable Overweight and obesity are defined as abnormal or excessive fat accumulation that may impair health. Body mass index (BMI) is a simple index of weight-for-height that is commonly used to classify overweight and obesity in adults. It is defined as a person's weight in kilograms divided by the square of his height in meters (kg/m2) Overweight and obesity are leading risks for global deaths. Around 3.4 million adults die each year as a result of being overweight or obese. In addition, 44% of the diabetes burden, 23% of the heart disease burden and between 7% and 41% of certain cancer burdens are attributable to overweight and obesity In 2012, more than 40 million children under the age of 5 were overweight or obese. Once

considered a high-income country problem, overweight and obesity are now on the rise in low- and middle-income countries, particularly in urban settings. In developing countries with emerging economies (classified by the World Bank as lower- and middle-income countries) the rate of increase of childhood overweight and obesity has been more than 30% higher than that of developed countries Overweight and obesity are linked to more deaths worldwide than underweight. For example, 65% of the world's population live in countries where overweight and obesity kill more people than underweight (this includes all highincome and most middle-income countries) ABOUT POULTRY INDIA Poultry India is an advisory body with a unanimous primary mandate of spearheading the Eat Right, Eat Healthy educational campaign to raise awareness on the scourge of

protein deficiency prevalent in the country. This campaign focuses on the need for a balanced daily diet consisting high proteins. Eat Right, Eat Healthy is just one of the many campaigns initiated by Poultry India. It also organises the Poultry India Expo, one of South Asia’s largest, which brings together global experts on bird flock nutrition, breeding, poultry equipment and animal health. The exhibition – now in its ninth year in 2015 - also provides insights into latest trends and best practices in poultry farming and breeding. Exhibitors from all over the world showcase their equipment, products and services to Indian and foreign visitors. A oneday technical seminar ‘Knowledge Day’ is also organised in conjunction with the Poultry India exhibition. The 2015 edition of Knowledge Day and Poultry India Expo will be held in Hyderabad’s HITEX City from November 24-27. The advisory body comprises heads of national organisations including

Indian Poultry Equipment Manufacturers' Association (IPEMA), National Egg Coordination Committee (NECC), CLFMA of India (Compound Feed Manufacturers Association), Poultry Federation of India (PFI), All India Poultry Breeders Association (AIPBA), Andhra Pradesh Poultry Federation (APPF), Telangana Poultry Federation (TPF), Poultry Breeders AssociationTelangana (PBA-T), Poultry Breeders Welfare Association Maharashtra (PBWA-Mah), West Bengal Poultry Farmers Association (WBPFA), Tamil Nadu Broiler Co-ordination Committee (TMBCC), Broiler Breeders Association - North (BBAN), Karnataka Poultry Farmers & Breeders Association (KPFBA), Indian Federation of Animal Health Companies (INFAH), Indian Poultry Journalist Association (IPJA) and All Odisha Poultry Association (AOPA). Please visit http://www.poultryindia.co.in and http://www.poultryprotein.com for more information.

Medical Device ASIA | November-December 2015 | 29


TENNIS STAR CAROLINE WOZNIACKI AND MUNDIPHARMA ANNOUNCE PARTNERSHIP IN GUINNESS WORLD RECORDSTM SETTING STYLE The 23-time WTA tournament winner’s international appeal to drive new marketing campaign for the BETADINE® range of product.

I

nternational tennis star Caroline Wozniacki was unveiled today as the newest Mundipharma brand ambassador for BETADINE®, the trusted name in homes and hospitals for antiseptic liquids, creams, sprays and ointments. A former women’s world number one for a total of 67 weeks, Ms. Wozniacki will be the face of a new BETADINE® integrated marketing and communications campaign that will be launched in selected emerging markets within Mundipharma’s network over the next 12 months.

"As a world-class athlete who never gives up and battles her way through the pain to victory on and off the court, Caroline perfectly embodies the BETADINE® vision of protecting people in the global fight against infection, while promoting healing and wound care,” said Raman Singh, President, Asia Pacific, Latin America, Middle East, and Africa, Mundipharma. "This partnership is a continuation of Mundipharma’s commitment towards building greater awareness around the importance of protecting our health and preventing infection in our daily lives.” BETADINE® products have been used and are trusted as an antiseptic for more than 50 years and consistently demonstrate strong efficacy against high strain viruses.

30 | November-December 2015 | Medical Device ASIA

Over the last 5 decades, BETADINE® formulations featuring povidone iodine1,2,3, a broad spectrum antimicrobial, have shown to be rapidly effective across various tough virus strains including those causing pandemic outbreaks1,3,4,5. “Tennis is one of the most physically demanding professional sports with a long season on tour, which makes it critical for professional tennis players to have an effective daily regime against infection and injuries,” said Ms Wozniacki. “BETADINE® has been a trusted partner in my personal journey, and I can’t wait to share how the products can help prevent and protect against infection.” In commemoration of their new partnership, Mundipharma invited Ms Wozniacki to help unveil a new tennis-related GUINNESS

WORLD RECORDS™ title at Asia Square, in the heart of Singapore’s business district. 16,000 tennis balls in different colours were connected together to create the world’s Largest Tennis Ball Mosaic. The tennis balls were designed to form a giant image of children at play, with each tennis ball representing the life of a child under the age of five that can be saved each day. This is the goal that UNICEF, the United Nations Children’s Fund, has been working tirelessly to achieve. Mr Singh also commented: “This new world record is a symbol of Mundipharma’s commitment to improving access to healthcare in our global communities and our support for UNICEF and its commendable vision of promoting the rights and well-being of every child.”


OGT licenses SNP probe technology to Baylor Miraca Genetics Laboratories

Proprietary technology allows superior LOH detection in challenging samples

O

xford Gene Technology (OGT), The Molecular Genetics Company, has entered into a deal with Baylor Miraca Genetics Laboratories (BMGL), licensing the use of OGT’s proprietary single nucleotide polymorphism (SNP) array probe technology. This novel technology overcomes the limitations of restriction enzyme-based SNP probe approaches previously employed at BMGL for loss of

heterozygosity (LOH) detection, allowing accurate array-based analysis of low-input DNA samples. Based in Texas (US), BMGL provides the highest-quality genomic services across the US and to over 16 countries worldwide, and as part of this objective, utilise aCGH arrays containing both copy number variation (CNV) and SNP probes to identify a broad range of genetic syndromes. For BMGL, OGT’s intensity-based SNP probe technology provides a superior alternative to restriction enzymebased approaches, which are unable to accurately analyse small amounts of DNA. The probes designed by OGT target each SNP allele, with the intensity ratio following hybridisation allowing reliable detection of LOH. To ensure robust and high-resolution LOH analysis, each probe set has

undergone extensive optimisation and validation. Vice President of Operations at BMGL, Mr. Sean Kim, commented: “We are dedicated to the rapid delivery of the most accurate genetic analyses. Through the application of OGT’s technology, we are now able to provide reliable array-based analysis of both copy number variation and loss of heterozygosity for challenging samples. We are now also looking to other areas of genetic analysis, expanding the use of this technology toward our complete portfolio.” OGT’s SNP probe technology is a key component of its extensive range of aCGH arrays covering multiple application areas, including cancer and constitutional research.

The latest product in development utilising this technology is the CytoSure Constitutional v3 +SNP array, which provides enhanced exon-level coverage of all developmental disorders. As a fully comprehensive approach to its genetic analysis strategy, BMGL also utilises OGT’s Cytocell FISH probes, and following a significant and successful validation programme, plans to further extend the use of these probes. Dr Mike Evans, CEO of OGT commented: “Through granting the licence, we are proud to be advancing the capabilities of such a prominent organisation as the BMGL with our SNP array probe technology and Cytocell FISH probes. This presents just the first step in an ongoing relationship, and we look forward to continuing this close cooperation.”

Medical Device ASIA | November-December 2015 | 31


Merck Brand Relaunched FUNDAMENTALLY REVISED BRAND IDENTITY REFLECTS TRANSFORMATION INTO A SCIENCE AND TECHNOLOGY COMPANY Merck Serono and Merck Millipore become Merck

M

erck, a leading science and technology company, today announced the relaunch of its brand identity. The fundamental revision of the visual appearance as well as the introduction of a new logo reflect the transformation into a global science and technology company. At the same time, the brand architecture at business level has been simplified. Outside the United States and Canada, the company will operate uniformly as Merck. "Merck has fundamentally changed over the past ten years," emphasized Karl-Ludwig Kley, Chairman of the Executive Board and CEO. "We have developed from a classic supplier of pharmaceuticals and chemicals into a global technology company. With our unique combination of highly specialized biopharmaceutical, life science and materials businesses, we are in a position today to offer solutions to support global megatrends such as health and digitization. The complete overhaul of our brand identity is to communicate this new direction vis-à-vis our customers, partners and applicants. We want to be recognizable and remain visible as Merck worldwide so as to strengthen our well-known brand name. For this we have deliberately rid ourselves of outdated features and will be focusing on a young and eye-catching image."

The investment in the Merck brand is part of the "Fit for 2018" strategic transformation and growth program, which includes the focus on innovative, technology-driven businesses as well as the modernization and expansion of global headquarters in Darmstadt, Germany. This also involves a more self-confident and at the same time clearer tone of voice, reflecting Merck's character and linking its pride in a nearly 350-year-old culture with scientific curiosity and a passion for research. With the introduction of the new brand design, the previously independent divisional brands Merck Serono and Merck Millipore will be eliminated. In the future, Merck Serono will operate as the biopharmaceutical business of Merck, and Merck Millipore as the life science business of Merck. "Following the two major acquisitions, the Merck Serono and Merck Millipore brands helped us to position the duality of existing and acquired businesses in the marketplace. We succeeded in doing so. That's why we are returning to the brand that we have been known under for nearly 350 years," Kley added. Product brands such as Erbitux or MilliQ will not be affected by this change. Merck holds the rights to the Merck name and brand globally. The only exceptions are the United States and

32 | November-December 2015 | Medical Device ASIA

Canada. The company will therefore continue to operate in these two countries as EMD Serono in the biopharmaceutical business, as EMD Performance Materials in the hightech materials business, as well as EMD Millipore in the life science business up until the planned acquisition of Sigma-Aldrich has been completed. Merck's visual image is fundamentally new. It is based on the concept of a vibrant science and technology company, and is inspired by the colorful and multifaceted shapes seen under a microscope. The new Merck design features expressive colors and shapes with a scientific look-and-feel. These are also reflected by the new company logo. In comparison with the former logo, it makes a bold statement; its design is less complex and can be used in different colors. "A comprehensive external and internal analysis showed that we must emotionalize our brand appearance to a much greater extent in order to be perceived as a vibrant technology company in the market and by applicants," said Walter Huber, Head of Group Communications. In addition, the new corporate design is to create a strong visual link to the Merck businesses in the United States and Canada. For this reason, the company is also introducing a striking, multi-colored

"M" in addition to the Merck logo. It is to indicate the membership of businesses and products to the Merck Group, independent of company names or regions. In its brand repositioning efforts, Merck was supported by FutureBrand, a leading brand agency that advises Bentley and Nespresso, among others, and also worked on the 2012 Olympic Games in London. About Merck Merck is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cuttingedge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of • 11.3 billion in 66 countries. Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.


7 out of every 10 Indians are Vitamin deficient: Metropolis Study

P

an India study of 14,96,683 samples reveals alarming statistics Mumbai, 13th October, 2015: Metropolis Healthcare – a multinational chain of diagnostic centres conducted an inclusive study on Vitamin D, Vitamin B12 and Vitamin B9 (Folic Acid) to observe the deficiency and sufficiency of Vitamins within the inhabitants across India. Metropolis conducted a comprehensive pan India study on 14,96,683 samples over a period of 3 years. The increasing trend of Vitamin deficiency is seen in all the age groups. Among the samples tested across 4 zones viz, North, South, East, West 75% of population has shown alarming levels of deficiency. Commenting on the study Dr. Sonali Kolte, General Manager, Medico Marketing said, “Indians have a lethargic attitude towards Vitamins. Vitamin deficiencies usually develop slowly over several months to years.

Symptoms of Vitamin D deficiency are usually vague muscle/joint pain, weakness, bone pain, tiredness, fatigue or even depression. Nowadays it is observed that people who are deficient in Vitamin D are more likely to have diabetes, regardless of how much they weigh. Early diagnosis and treatment can help control the symptoms and prevent health related problems.” The Study In an analysis of over 14, 96,683 patients who underwent Vitamin tests, the following trends emerged. • 81.28% of all samples tested were deficient in Vitamin D • 21.02% of all samples tested were deficient in Vitamin B12 • 15.06% of all samples tested were deficient in Vitamin B9 Vitamin D: It has been a general belief that vitamin D deficiency is uncommon in India because of abundant sunshine. There is,

AGE GROUP WISE DEFICIENCY OF VITAMIN D IN BELOW TABLE Vitamin D 1 to 20 Deficiency Sufficiency Grand Total % of Deficiency

20 to 40 23376 5399 28775 81.24

40 to 60 96268 19019 115287 83.50

however, now increasing evidence that this is not true. Vitamin D deficiency has reached epidemic proportions in India despite ample sunshine.Vitamin D is unique because it is a vitamin synthesized by the body and it functions as a hormone. Vitamin D is important for overall good health and strong and healthy bones. It’s also an important factor in making sure your muscles, heart, lungs and brain work well and that your body can fight infection. Your body can make its own vitamin D

60 to 80 & Above 94926 240540 29321 74010 124247 314550 76.40 76.47

from sunlight. You can also get vitamin D from supplements and a very small amount comes from a few foods you eat. They are vital for everyone and ensure that your body works well and is able to fight illness and heal well. Vitamin D manages calcium in your blood, bones and gut and helps cells all over your body to communicate properly. Most common reason to have deficient levels of vitamin D is due to limited sunshine exposure. Studies suggest that vitamin sufficiency may even help ease

Gender wise patterns emerged as below Zone Male Female Average Vitamin D Deficiency North Zone 81.41% East Zone 85.10% West Zone 82.06% South Zone 81.27%

75.97% 83.23% 78.54% 82.67%

78.69% 84.17% 80.30% 81.97%

Vitamin B12 Deficiency North Zone 29.70% East Zone 22.94% West Zone 23.89% South Zone 23.74%

23.53% 21.05% 15.43% 7.90%

26.62% 22.00% 19.66% 15.82%

Vitamin B9 Deficiency North Zone 15.53% East Zone 16.28% West Zone 17.51% South Zone 29.33%

9.36% 13.23% 9.25% 10%

12.45% 14.76% 13.38% 19.67%

Medical Device ASIA | November-December 2015 | 33


OGT launches Cytocell FISH probe for bladder cancer Cost-effective, ready-to-use kit enables appropriate testing strategies for reliable diagnoses

O

xford Gene Technology (OGT), The Molecular Genetics Company, has launched its CE-IVD labelled Cytocell Aquarius® P16/3c/7c/17c Probe Kit, a cost-effective, ready-to-use fluorescence in situ hybridisation (FISH) probe kit for non-invasive detection of bladder cancer — for sale in Europe. Bladder cancer is becoming increasingly prevalent, and in 2012 was reported as the 5th most common cancer in Europe1. While cytology screening is commonplace for diagnosing bladder cancer, a recent update to UK NICE guidelines2 recommended the use of FISH. FISH methods have been shown to have the same specificity as cytology screening and greater sensitivity in detecting bladder cancer cells3-4.

well-known tumour suppressor gene p16 (CDKN2A) — commonly deleted in bladder cancer7-8.

Raphael Hospital in Milan, who extensively tested the probe on a large series of samples, commented: “We found Cytocell’s bladder cancer probe kit easy to use, with bright results that were simple to interpret.

The economical Cytocell Aquarius P16/3c/7c/17c Probe Kit contains ready-to-use reagents and has an easy-to-use protocol, reducing the potential for errors and increasing convenience. Specific, clear, highintensity signals with minimal background deliver quality, reproducible and easy-to-score results ensuring clinicians can be confident in reporting. Dr. Lorenza Pecciarini, cytogeneticist at the Saint

It was straightforward to incorporate into our existing cytology workflow and was highly reproducible. This product offers an accurate and cost-effective technology for the diagnosis of bladder cancer.”

FISH analysis for bladder cancer is also particularly useful for monitoring treatment outcome and can aid in reducing patient mortality by detecting bladder cancer recurrence up to six months earlier than other methods5. Carrying the CE mark for in vitro diagnostic use within Europe, OGT’s product accurately detects in urine samples the three most common aneuploidies associated with bladder cancer (chromosomes 3, 7 and 17). It also detects deletions of the 9p21.3 locus6 containing the 34 | November-December 2015 | Medical Device ASIA

Martin Lawrie, Managing Director at Cytocell said: “The decision to expand OGT’s cancer portfolio and specifically Cytocell pathology probes, demonstrates OGT’s commitment to the fight against cancer. Supported by recent guidelines, our new bladder cancer probe kit delivers a convenient means to confident diagnoses, backed by the great customer support that OGT has become renowned for.” For more information, please visit www.cytocell.co.uk.


MEDICAL FAIR ASIA to host inaugural Asian edition of MEDICINE + SPORTS CONFERENCE in 2016

First ever MEDICINE + SPORTS CONFERENCE ASIA to feature greater focus on Southeast Asia, bringing together sports medicine experts, healthcare providers, physicians, fitness trainers and industry players to discuss innovations in sports medicine and pertinent healthcare challenges in the region To be held on 1st Sep 2016 during MEDICAL FAIR ASIA 2016 at a new venue, the Marina Bay Sands Singapore

T

he MEDICAL FAIR ASIA, Southeast Asia’s most definitive event for the medical and healthcare industry, will host the first ever Asian edition of the MEDICINE + SPORTS CONFERENCE in 2016. The inaugural MEDICINE + SPORTS CONFERENCE ASIA will be held on 1st September 2016 during MEDICAL FAIR ASIA 2016 at a new venue, the Sands Expo & Convention Center, Marina Bay Sands Singapore. The conference is jointly organized by Messe Düsseldorf Asia and Navispace AG, with the support from founding cooperation partners namely; Sports Medical Association Singapore (SMAS), Exercise is Medicine Singapore (EiMS), FIMS (International Sports Medicine Association) and WT Wearable Technologies Group. Founded in 2013 at the largest medical trade show MEDICA, the internationally established MEDICINE + SPORTS CONFERENCE has repetitively attracted great speakers and high-level attendees from around the world. The inaugural Asian edition will feature

eminent speakers on topics such as physical activity as a key to disease prevention, defining health and fitness guidelines, creating the right activity programs for athletes and non-athletes, vital data and performance monitoring, digital systems in elite and recreational sports as well as new digital solutions such as new activity trackers, monitoring devices and other health gadgets. The conference also aims to feature a greater focus on the pertinent healthcare challenges in the Southeast Asia region, using the opportunity provided by MEDICAL FAIR ASIA, with relevant industry participation and attendance of quality trade buyers and decision makers, to generate highlevel exchanges and discussions. The established MEDICINE + SPORTS CONFERENCE has been brought to Asia in view of the booming sports medicine market in this region. According to market research solution ReportLinker, the Asia Pacific sports medicine market is estimated to grow at a compound annual growth rate (CAGR) of 6.96% and is expected to reach US$3.85 billion by the end of 2019. At the same time, with the rapid economic development and increasing adoption of modern lifestyle habits in Southeast Asia, rising noncommunicable diseases like cardiovascular diseases, chronic respiratory diseases, and diabetes have become one of the major healthcare challenges in the region. According to the World Health Organization (WHO), 62% of all deaths in the region are due to noncommunicable diseases and 48% of affected persons are aged below 70 years. Mr Gernot Ringling, Managing Director of Messe Düsseldorf Asia, said: “Over the years, we have seen sports medicine advance by leaps and bounds worldwide, making it important for stakeholders and industry players in this region to remain at the forefront of the

latest innovations and to address the most prominent healthcare challenges. I am very excited for Messe Düsseldorf Asia to partner with Navispace AG in bringing MEDICINE + SPORTS CONFERENCE to Asia for the first time. This will enhance the experience of all our delegates at MEDICAL FAIR ASIA 2016 and add significant value to the event. MEDICAL FAIR ASIA is proud to host the inaugural Asian edition of MEDICINE + SPORTS CONFERENCE.” “It is most appropriate and timely that we base the Asian edition of MEDICINE + SPORTS CONFERENCE at MEDICAL FAIR ASIA, the hallmark event for Asia’s medical and healthcare sector,” said Dr Sonja Sulzmaier, Managing Partner of Navispace AG. “Healthcare investment and the emphasis on sports medicine are shifting towards Asia, particularly in the Southeast Asia region. It is imperative to facilitate the right dialogue and networking platform to discuss how technology and innovation in this sector can help address some of the region’s healthcare challenges. We are confident that this inaugural conference will deliver valuable opportunities for discussions and development of solutions to meet the challenges of the fast changing healthcare landscape in this region.” MEDICAL FAIR ASIA 2016, organized by Messe Düsseldorf Asia, will be held from 31 August to 2 September 2016 at a new venue, the Sands Expo & Convention Center, Marina Bay Sands Singapore. As a testament to the significance of the event for the medical and healthcare industry, 1,000 exhibitors from 45 countries, 20 national pavilion and country groups and 15,000 qualified trade buyers and

decision makers are expected to participate in this 11th edition. The 3rd edition of MEDICAL MANUFACTURING ASIA in 2016 will also colocate with MEDICAL FAIR ASIA 2016 to offer synergistic opportunities for specialists sourcing diversified solutions for the healthcare and medtech industries. Focused on the medical technology and medical manufacturing sector, MEDICAL MANUFACTURING ASIA is jointly organized by Messe Düsseldorf Asia and the Singapore Precision Engineering & Technology Association (SPETA).

About MEDICAL FAIR ASIA 2016 Organized by Messe Düsseldorf Asia, MEDICAL FAIR ASIA is part of the ”World of MEDICA” brand and has established itself as the region’s leading international exhibition on hospital, diagnostic, pharmaceutical, medical & rehabilitation equipment & supplies. Following its successful growth path since its inception in 1997, MEDICAL FAIR ASIA acts as the gateway to Asia for global industry players by providing the perfect platform to showcase the latest industry innovations, to network and do business.

For more information, please contact: Maria Wesson / Liliane Lye Tel: +65 6332 9652 / +65 6332 9624 Email: maria@mda.com.sg / liliane@mda.com.sg Exhibitor contact: Daphne Yeo Tel: +65 6332 9682 Email: daphne@mda.com.sg Or visit www.medicalfair-asia.com

About Messe Düsseldorf Asia Messe Düsseldorf Asia is a subsidiary of Messe Düsseldorf in Germany, one of the world’s leading trade fair organisers, responsible for organising more than 20 global No. 1 exhibitions in various industries including medicine and health, specifically MEDICA, COMPAMED and REHACARE INTERNATIONAL held in Düsseldorf, Germany. With extensive expertise in organising trade fairs in Southeast Asia, Messe Düsseldorf Asia has developed a portfolio of numerous trade fairs in the region since 1995. For more information, please visit www.messe-duesseldorf.de/MDA Medical Device ASIA | November-December 2015 | 35


CPhI Istanbul 2016, A Meeting Point for International Health and Pharma Industry 01-03 June 2016, Istanbul Congress Center, Istanbul TURKEY

UBM will organize CPhI Istanbul 2016 at Istanbul Congress Center from 1st -3rd June 2016. CPhI Istanbul 2016 is the foremost business platform to access the growing Pharma markets both in Turkey and MENA and Central Asia & Caucasus Regions. The Hosted Buyer Program will also be organised with Ministry Of Economy, Matchmaking Program, Conference Program during the CPhI Istanbul 2016.

Connect, network and interact with 200+ exhibitors from 26 countries, 4.000 attendees from 80+ countries at Eurasia’s dedicated pharma event! Pavillions in CPhI Istanbul 2016 : China pavilion, Italian pavilion, India pavilion CPhI Istanbul and colocated events ICSE, P-MEC, InnoPack is your ultimate one-stop-shop for regional pharma solutions. Hosting exhibitors from ingredients, contract services and technology through to packaging and machinery. CPhI Istanbul 2016 brings you the entire Pharmaceutical supply chain under one roof.

Why Istanbul?

Istanbul’s strategic position makes this event the perfect place to meet with regional suppliers from Europe, Central Asia and the MENA region. The Turkish Government aims to make Turkey one of the world’s top ten 36 | November-December 2015 | Medical Device ASIA

economies in health services by 2023 by increasing R&D expenditures to 3% of GDP and by increasing exports to USD 500 billion. Key reasons to visit: • Get access to the regional pharma markets and meet with exhibitors from Turkey, the Balkans, Central Asia, Middle East and North Africa. • Guaranteed industry networking - meet regional drug manufacturers and suppliers of pharma ingredients, machinery, packaging solutions and contract services. • Get the latest market insights and find out about the latest offerings of exhibitors during the exhibitor showcases. • Tap into the strong growing regional pharma markets and meet leading companies from the Eurasian region, such as Deva, Nobel Ilac, Pharmactive and many more. For more details, please visit: www.cphi-istanbul.com


MediAngels bags Healthcare Excellence Award MediAngels.com, reputed to be the world’s first online hospital, was awarded as "Best Online Healthcare Provider 2015" at Frost & Sullivan's India Healthcare Excellence Awards. The award was given in keeping with MediAngel's commitment and contribution to bringing a change in the healthcare delivery system. While receiving the award Dr.Debraj Shome, Founder and CEO MediAngels.com said, “This is a huge inflection point in India. Just like Indians jumped to the mobile, because of a lack of enough landlines, an online hospital like MediAngels.com will revolutionise the healthcare delivery sector and make India jump from physical hospitals to online hospitals. This is the only way for all of India to get top quality healthcare - delivered through the phone, via the internet." We wish to thank all our supporters for their love and affection, as we look to galvanise healthcare in India.

Government of India, Department of Science and Technology. Being a medical expertise company, Mediangels aims to match the best doctor to every disease. To set up a tertiary hospital in every district in the country is a daunting task for the government which would cost about $1 trillion. Hence, ehealthcare becomes the best option. The health professionals that

form the core team of Mediangels are in tune with the changing dynamics of medical practice worldwide and the modern-day consumer’s expectations from healthcare. About MediAngels.com MediAngels.com is the world’s first online hospital. With a network of over 350 medical experts handpicked from across the world, MediAngels.com delivers quality healthcare and second opinion at the click of a button. The platform offers patients access to qualified, trustworthy super-specialists for any ailment, anytime of the day in the comfort of home, securely. MediAngels.com constantly enriches patient’s experience as a healthcare consumer by adopting new and innovative technologies.

MediAngels, a four-year-old startup, provides services including online video consultation and online medical records. Voted as the most innovative start-up in the entire APAC region in 2012 by Intel, it is funded by marquee investors which include HDFC Holdings, VentureEast, Medical Device ASIA | November-December 2015 | 37


Solid-state silicon photomultipliers offer performance and application advantages growth markets. The company produces in-house and along the value-added chain from component to system level. With over 800 employees, we are represented at six German locations and also have development, production and sales sites in the USA, Canada, China, the Netherlands, Great Britain, France, Sweden and Denmark along with a worldwide partner network.

F

irst Sensor extends its range of optical sensors with innovative solid-state silicon photomultipliers (SiPMs) for the detection of ultra-low light levels down to single photons. Compared to conventional photomultiplier tubes, SiPMs offer significant advantages such as low operating voltage, excellent temperature stability, immunity to magnetic fields and a much smaller size for easy system integration. The detectors are optimized for near ultraviolet (Series SiPM-NUV) or red, green and blue (Series SiPM-RGB) light detection with peak sensitivities at 420 nm or 550 nm. The silicon photomultipliers consist of a matrix of multiple avalanche photodiode (APD) micro-cells operated above their breakdown voltage (Geiger mode). NUV- and RGB-SiPMs from First Sensor feature extremely low temperature coefficients of the breakdown voltage and gain, which allows for highly accurate and stable measurements. Enhanced materials and semiconductor technology enable

low-noise devices with reduced dark count rate, crosstalk and very low afterpulsing probability typ. <4 %. The precision SiPM detectors are designed to achieve very high gain (>106) and high photon detection efficiencies. The edgeless SiPM dies ensure high cell fill-factors and maximized active areas in array arrangements. The Chip-Scale-Package (CSP) provides a cost-effective and RoHS compliant solution suitable for reflow soldering. For custom specific applications First Sensor develops and manufactures arrays, modules and complete systems for OEM customers worldwide. Important features of the SiPM-NUV and SiPM-RGB silicon photomultipliers: Ultra-low light detection down to single photons Low operating voltage High gain and low noise Immunity to magnetic fields

38 | November-December 2015 | Medical Device ASIA

Typical applications of silicon photomultipliers from First Sensor include high energy physics, medical diagnostics, nuclear medicine, homeland security and analytical instruments. Due to the immunity to external magnetic fields, SiPM detctors are ideal for medical imaging applications such as combined tomography systems using magnetic resonance tomography (MRT) and positron emission tomography (PET) or single photon emission computed tomography (SPECT). Further product information: www.first-sensor.com/sipm About First Sensor AG First Sensor AG is one of the world's leading suppliers in the field of sensor systems. Our company develops and manufactures both standardized and tailor-made sensor solutions for the detection of light, radiation, pressure, flow, level and acceleration for applications in the Industrial, Medical and Mobility

We guarantee our compliance through regular successful certifications of the sites according to ISO/ TS 16949, ISO 14001, EN ISO 13485, EN 9100 and ISO 9001 matching the respective business field. First Sensor AG is listed in the Prime Standard of the German stock exchange in Frankfurt. For more details on First Sensor, please visit: www.first-sensor.com First Sensor AG Peter-Behrens-Str. 15 12459 Berlin Germany T +49 30 6399 2399 Technical press contact: Doris Tischer Director Marketing Communications E-mail: technical.press@firstsensor.com T +49 89 80083-48


Frost & Sullivan Recognizes Innovative Strategies and Stellar Performance at its 7th Annual India Healthcare Excellence Awards 2015

O

ver the years, Frost & Sullivan’s Healthcare Practice has recognized distinguished companies and individuals for their significant achievements and seamless contribution to the country’s healthcare industry. Continuing its efforts, Frost & Sullivan successfully hosted the seventh edition of its India Healthcare Excellence Awards on October 9, 2015 at Hyatt Regency, Mumbai. The awards banquet, attended by the prominent figures in the healthcare industry celebrated the success of the winning enterprises. Awarded for their growth strategies, due diligence in development and innovation, showcasing best practices adoption and host of other critical factors, the 25 award recipients at the 7th Annual Healthcare Excellence Awards represented the best-in-class of the healthcare business. On the occasion, Sandeep Sinha, Vice President, Healthcare Practice, South Asia and Middle East, Frost & Sullivan said, “The award recipients of this year’s Healthcare Excellence Awards represent a mix of established enterprises and innovative start-ups, who with their capability to revolutionize the healthcare industry, are expected to bring in groundbreaking

innovations and novel practices in India’s healthcare system. Frost & Sullivan is proud to recognize their efforts and encourage them in their future endeavor.” This year, the awards were presented across four major award categories: Pharmaceuticals and Biotechnology, Healthcare Delivery Services, Medical Technologies, and Research-based Awards. Following a rigorous process of selection, the awards jury comprising of eminent industry experts, key opinion leaders, and visionary innovators, rated nominees across eight to 10 parameters, backed by the research data from Frost & Sullivan and their market knowledge and domain expertise. Besides these categories, there were two Special Awards conferred by Frost & Sullivan to exemplary individuals who have contributed significantly to the healthcare industry for its advancement and furtherance.

Medical Device ASIA | November-December 2015 | 39


Diatron to launch new 5-part veterinary hematology analyzer at Medica “The Abacus Vet5 provides excellent usability and LIS integration�

T

he Diatron Group, global provider of hematology and clinical chemistry analyzers, will launch a new 5-part differential veterinary hematology analyzer - the Abacus Vet5, in Dusseldorf at the forthcoming Medica show on the 16-19 November. This will be introduced on booth 3A 07 alongside Diatron’s new 3-part differential human hematology analyzer, the Diatron Aquila, which delivers lower costs and wider range of use, from small laboratory to point-of-care environments.

reagent pack for the new Abacus Vet5 includes a special hardware key which transfers important product data (e.g. lot number and expiry date) automatically to the analyzer, eliminating transcription errors while protecting the system from being used with non-recommended reagents. New 3-part differential human

The Abacus Vet5 analyzer has a completely new look and is operated via a large capacitive touch screen, greatly enhancing user experience. New features include: increased on-board data storage capability of up to 5000 records including histograms; a new comprehensive QC package; and more data export/connectivity functionalities, providing improved communication with laboratory information systems (LIS). The new analyzer uses well-proven Diatron Veterinary reagents which enable a wide range of hematological parameters to be tested on a broad panel of animal species. Each

40 | November-December 2015 | Medical Device ASIA

hematology analyzer - Diatron Aquila Also on booth 3A 07, the Diatron Aquila, a new 3-part differential hematology analyzer (60 test /hour throughput) will be introduced to the laboratory world for the first time. This innovative analyzer has been specially designed to provide unique solutions to the many needs

of the rapidly evolving worldwide hematology markets. Requiring minimal bench space, this small analyzer has low reagent consumption (<10ml), needs only a small sample size (10ul) and has an on-board reagent pack** (sufficient for circa 200 measurements). www.diatron.com


EKF’s PointMan™ used in successful liquid biopsy research COMPARATIVE STUDY OF TUMOR BIOPSY V NONINVASIVE BLOOD-BASED ANALYSES PUBLISHED

P

ointMan™ DNA enrichment technology for highly sensitive detection of genetic mutations For high resolution image, please contact sarahp@alto-marketing.com Cardiff, UK – 15th October 2015 – EKF Diagnostics, the global in vitro diagnostics company, announces that results from a study involving EKF Molecular’s PointMan™ DNA enrichment technology have been published in Clinical Cancer Research [1], a journal of the American Association for Cancer Research which focusses on innovative clinical cancer research studies. The study comparing tumor biopsy with noninvasive blood-based analyses brings together experts from four major US cancer centers involved in the ‘Stand Up to Cancer’ program - Massachusetts General Hospital, Harvard Medical School, The University of Texas, and Weill Cornell Medical, NY. PointMan DNA enrichment technology was used within the study for the highly sensitive detection of genetic variations in circulating tumor cells (CTCs) in blood samples from nonsmall cell lung cancer patients.

T790M, the acquired resistance EGFR mutation, by tumor biopsy versus non-invasive blood-based analyses”, focused on identifying the epidermal growth factor receptor (EGFR) T790M mutation, which is associated with resistance to certain cancer drug treatments, using alternative methods to invasive tissue biopsies. The study identified the T790M mutation from a standard lung biopsy and then compared these results with tests on blood samples containing CTCs or circulating tumor DNA (ctDNA) from the patient’s cancer. The T790M mutation from the CTC samples was enriched using EKF Molecular Diagnostics’ PointMan EGFR T790M DNA enrichment kit to enhance the sensitivity of the test procedure

allowing accurate genotyping to take place. A successful outcome of this research would be key for those developing novel EGFR inhibitors capable of overcoming T790M associated resistance, whereby clinicians will be able to use regular blood tests to monitor progress rather than painful and intrusive lung biopsies. Julian Baines, CEO of EKF Diagnostics said: “This is the first published scientific paper to feature PointMan and, importantly, the authors are primarily from four US cancer centers that are instrumental in the ‘Stand Up to Cancer’ program. These results show that liquid biopsy is well on the way to becoming a realistic diagnostic alternative to tissue biopsy, particularly when several samples need to be taken during the treatment period. Importantly this study shows that PointMan enrichment technology could become an essential part of routine blood tests for cancer diagnosis and treatment monitoring.” The scientific paper can be viewed here: http://clincancerres.aacrjournals.org/content/early/2015/10/07/10780432.CCR-15-1031.abstract?sid=92fd4483-c733-4004-aaf5-4e8ff00eaabe

In September 2014, EKF announced a two year research collaboration with Massachusetts General Hospital to develop PointMan assays that can effectively detect treatable cancer mutations in blood samples. This study shows that, subject to further clinical validation, liquid biopsy (tumor typing using blood as the sample source) is a realistic diagnostic opportunity with significant advantages over tissue biopsy. The study, entitled “Detection of Medical Device ASIA | November-December 2015 | 41


Arogya Finance Join Hands with Dr. Reddy’s Laboratories to Provide Medical Loans for the Financially Weak Facilitates medical loans for Resof, a drug for treatment of Hepatitis C virus (HCV) infection and a few other therapies.

A

rogya Finance, a social healthcare venture based in Mumbai tied up with Dr. Reddy’s Laboratories a multinational pharmaceutical company for providing medical loans for treatment of Hepatitis C. Arogya Finance will facilitate easy Equated Monthly Installments to patients to pay for the drug for Hepatitis C and a few other therapies provided by Dr. Reddy’s Laboratories. “According to World Health Organization over 12 million people in India suffer from chronic hepatitis C leading to unexpected healthcare expense burden. Arogya Finance in association with Dr. Reddy’s has taken an initiative to offer medical loans at reasonable terms and making it available at the right time, right place and reaching out to the patients in rural India. We are providing a one-stop financial solution for people in need whenever and wherever there is an unforeseen medical emergency.” said Mr. Jose Peter, Co-Founder and CEO of Arogya Finance. Arogya Finance does not require collaterals or formal income proof which is mandatory in other forms of finance. Arogya Finance offers a loan and makes it easily available

within 24 hours. The company offers medical loans to the traditionally unbankable, using a psychometric test as an innovative risk assessment tool to enable evaluation of the credit risk profile of people outside the formal banking system. The borrowers can repay the loans in EMIs of upto 36 months and is calculated in a way that it does not exceed 25% of the total family income. Arogya Finance has been recognized as one of India’s most unique social innovators by Innovations in Healthcare, an organization founded by McKinsey, USAID and the World Economic Forum and Social Entrepreneurship Accelerator at Duke (SEAD). With over 150 healthcare delivery partners and presence in 10 states, Arogya is also implementing a unique concept of an Arogya Card, a pre-approved medical loan for the entire family, across the nation. About Arogya Finance: (www.arogyafinance.com) Arogya Finance, co-founded by Mr. Jose Peter and Mr. Dheeraj Batra, is a social healthcare venture, which offers medical loans to the traditionally un-bankable, using innovative risk assessment tools that allows them to finance people

42 | November-December 2015 | Medical Device ASIA

outside the formal banking system. The business model is structured in a way, that it directly pays the medical bills of an individual to the hospital or the healthcare service provider. Arogya Finance has partnered with hospitals and other healthcare providers to ensure that people can access medical loans for themselves and their families. Patients borrow from and repay Arogya Finance directly leaving them free to get treated wherever they choose to do so. To ensure maximum reach, Arogya Finance has developed a path-breaking proprietary approach, which enables it to lend to even those who fall outside the formal sector. Arogya’s approach does not require collateral or income proof. Arogya has developed a truly Indian approach to solving the healthcare affordability issue in India.


BigChemist.com is an initiative for creating an integrated online market place for healthcare product & services across value chain with focus on serving B2C & B2B as Omni channel experience

B

igChemist.com is an A3T Retails Pvt Ltd company founded in May 2013 head quartered in Delhi. BigChemist.com is India's largest e-platform for genuine Medicines and Healthcare products.

The aim behind BigChemist.com is to facilitate customers with genuine medicinesand other healthcare products at affordable prices. BigChemist.com aims to create awareness around availability of substitutesthus enabling customer to take informed decisions at the convenienceright in the privacy of their home and office. The company was found on the grounds of giving simple, effective solutions to people in need of Medicines online in India. Big Chemist offers India's largest range of genuine Medicines, health products across categories and all major brands at one platform. BigChemist is run by a core team of highly qualified professionals with experience and strong skills in Healthcare, Pharmacy Benefits, Technology, Operations and Customer Management. A team of trained nutritionists, counsellors and product experts help customers in choosing the right product/service via email and phone. Big

Chemist has both online presence in www.bigchemist.com (having over 1.2 lakh visitors) and physical brick & mortar storesincluding captive & local neighbourhood pharmacy partners in NCR region. Big Chemist sources the best health & wellness products from across the globe & provides them to every Indian via online shopping. The offering covers categories like Health &Nutrition, health instruments, Personal Care, Beauty, Parenting &evolving Healthcareservices. It partners directly with the brands and their authorized channels, to ensure strict quality control and deliver 100% genuine products. BigChemist.com strives to excel in its vision of becoming a dependable, household name in India, and offering customers direct access to genuine healthcare products at best prices.

Medical Device ASIA | November-December 2015 | 43


ACD’s RNAscope® Technology Achieves 300-publication Milestone “Use of next generation RNA In Situ Hybridization across a diverse array of applications”

A

dvanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based RNA analysis tools, is celebrating a significant milestone. Over 300 peerreviewed research papers have now been published that feature ACD’s RNAscope technology as a core part of the research methodology, reflecting its facility in advancing the latest biological research in both academia and industry. RNA in situ hybridization (ISH) is a valuable tool for studying spatial and cell-specific gene expression, while preserving tissue architecture. ACD’s RNAscope represents a breakthrough advance in RNA ISH, implementing a proprietary signal amplification system to enhance both sensitivity and specificity, producing a high-performance assay that is also quick and easy to use. As awareness has spread of how RNAscope ISH can accelerate a variety of studies, its rise in uptake has translated to a rapid increase in published research. Thus far in 2015, the number of new publications has already exceeded 150, more than the total number of publications from all the previous years combined, signaling acceleration in technology adoption. Chief

Scientific Officer, Dr. Xiao-Jun Ma, commented: “This rapid increase in publications speaks directly to the value of RNAscope technology in many fields of research. Spatially mapped single-cell gene expression data are crucial to understanding the development, structure and function of complex tissues at the molecular and cellular level. However, obtaining such data has been a huge bottleneck due to technical difficulties of traditional RNA ISH methods and the loss of contextual information with grindand-bind assays. With RNAscope, such data can be generated within weeks from a concept to publication quality images.” The papers range from basic research in developmental biology, neuroscience, stem cells and ophthalmology, to translational research and diagnostic development of biomarkers in cancer and infectious diseases, in respected journals such as Nature, Science, Cell, New England Journal of Medicine, PNAS, PLoS One, and Clinical Cancer Research. Browse ACD’s publication database online. For further information, you can also visit www.acdbio.com

44 | November-December 2015 | Medical Device ASIA


Aarogyam Energy Jewellery brings to you ideal, unique and healthy gifting options

Aarogyam Biomagnetic Titanium Bracelet by Aarogyam Energy Jewellery

T

hey are ideal, unique and healthy gifting options this Diwali. In the current times when our loves are facing troubles of blood pressure, sugar levels and stress, there could be no better gift than energy jewellery that balances your magnetic field for stable blood flow and peaceful state of mind. Aarogyam Energy Watch by Aarogyam Energy Jewellery Aarogyam Energy Watch helps to release tension from muscles. The magnetic fields accelerate toxin flushout from body and gently message the cells to release more endorphins. Regular wear of magnets and lava stones also enhances immunity and improves the anti-infective activities of the body. This stylish and affordable Energy Watch comes with stainless steel casing and strap.

Aarogyam Biomagnetic Titanium Bracelet is made up of Titanium / Stainless Steel metal with pure Neodymium magnets (King of Magnets) Neodymium is a Rare Earth Metal. It helps in regulating Blood Circulation which helpful to solve many health problems related to diabetes, blood pressure problems, some of dangerous pains of a human body.

The Aarogyam Quantum Science AM Pendant itself is designed to resonate at zero point energy and help the human bodies’ bio energy field restore itself to its natural homeostasis condition. Wearing Aarogyam AM energy pendant will help to increase the body’s ability to fight stress that may come from everyday life and also help to combat the effects that can come from living in a e-smog environment. Available on: www.unltdoffers.com

Aarogyam Quantum Science AM Pendant by Aarogyam Energy Jewellery The Aarogyam Quantum Science AM Pendant is based around the same zero point energy concept as the M wand. The Aarogyam Energy AM pendant is designed and created using certain advanced minerals that is held in a titanium case, fusion and processed by AMized Fusion Technology.

Medical Device ASIA | November-December 2015 | 45


Advanced Cell Diagnostics Launches New Website and Online Store “Better serving the scientific community, the new site is equipped with a fresh design and interactivity, and features e-commerce capabilities”

A

dvanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based RNA analysis tools, has announced the launch of its new website, www.acdbio.com. In response to the growing popularity of ACD’s proprietary RNAscope® in situ hybridization (ISH) technology, the site has been completely redesigned to better serve its thousands of monthly visitors. The new site graphically presents RNAscope technology, with

streamlined navigation to interactively present all resources. New visitors can now rapidly and visually learn about the technology, see its applications and access relevant peer-reviewed publications. With fast and convenient e-commerce capabilities, ACD’s customers will also be able to access sales quotes in real time and place online orders, significantly easing the buying process.

company’s continual dedication to customer service. Tom Olenic, Chief Commercial Officer of ACD, commented: “Of our monthly web visits, the majority are from scientists who are new to our technology, searching for how RNA ISH can enrich their research, so we prioritized visual presentation of our technology and diverse application content. On the other side, the sharp growth of our install base requires that we adopt modern B2B infrastructure to scale and ease the transactional processes. Scientists are busy; so searching through our 7,000 gene probe catalog, which grew by over 150% this past year, and selecting just the right probe for the right gene has to be fast and easy.”

In light of its ability to sensitively and specifically detect and quantify RNA targets in the context of the cell or tissue, RNAscope ISH is becoming an increasingly popular technology, with over 300 peer-reviewed publications to date featuring RNAscope ISH – currently at the rate of over 17 new publications per month.

ACD will continue to expand its online store features, soon to support customers outside of the US and also those who place orders using purchase orders. The new website is one facet of ACD’s initiative to incorporate modern business infrastructure to support and intimately interact with its growing customer base.

The new website reflects this business growth, together with the

For more information, you can see the new website at

46 | November-December 2015 | Medical Device ASIA

www.acdbio.com. About Advanced Cell Diagnostics Advanced Cell Diagnostics, Inc. (ACD) is a leader in the field of molecular pathology, developing cell and tissue-based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. RNAscope assays are currently used by thousands of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases. ACD’s industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners’ targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com


STARLED3 NX Surgical led lamp STARLED3 NX is a lamp manufactured by ACEM based on the Next generation LED technology, assuring cold light, long life and low energy consumption. The lamp is suitable for countless applications both for surgery and operating room. It is ideal for diagnosis, dental sector, gynecology, dermatology, general medicine and surgery. STARLED3 NX grants a homogeneous and shadowless light thanks to its special LED optics created by ACEM Medical Company that directs light beams at best according to the needs. The visual area is perfectly illuminated assuring both excellent visual comfort and working conditions. Its next generation LEDs produce an unparalleled quality of light with a colour temperature (CCT) of 4.500 °K and a colour rendering index (CRI) of 95. STARLED3 NX has a light intensity of 130.000 lux with consumption of 69W. The life cycle of its LEDs is about hours.

a low energy 50.000

STARLED3 NX is composed by three reflectors that a well-blended and intense cone of light focusable the automatic adjustment of the light spot diameter. practical and compact design makes it perfect for several lamp is ergonomic, easy to move and to and suitable for the laminar flows of the room.

produce through Its slim, uses. The position operating

Its ENDO function (light for endoscopy) gives the possibility to use STARLED3 NX for minimalsurgery too. The easy -to-clean shape and material STARLED3 NX as well as its removable, sterilizable to-grip handle assure an excellent cleanliness.

invasive of and easy-

Functions are adjusted by its innovative easy-to-read, ergonomic and easy-toclean I-SENSE® control panel. With a simple touch it can manage easily and accurately: • ON/OFF function 4 | July-August 2015 | Medical Device ASIA

• Light • DoF • ENDO

intensity adjustment Depth of Field - for a deep light - Light for endoscopy ideal for minimal-invasive surgery • SIZE - Light spot diameter adjustment to focus the operating area • SYNC - Function (optional) useful to synchronize controls of the combined lamps: STARLED3 NX double (twin dome configuration) and STARLED3 NX together with STARLED3 NX or STARLED7 NX. STARLED3 NX is available in the following versions: Ceiling mounted, (Single, double configuration or together with other STARLED NX lamps) , Wall mounted, Trolley mounted ( ABPS battery on demand) . ABPS is a rechargeable battery powered system made by ACEM Medical Company dedicated to power surgical lamps as by European Directive 93/42/ EEC. STARLED3 NX with ABPS has the same performance and appearance, since the structure containing the battery is within the trolley base. The structure which covers and protects the battery is made of resistant plastic, and its dimensions are: 550 x 340 x 240 mm. The control panel on the structure allows managing all fundamental parameters, such as residual charge, type of power supply, recharge status and electrical power supply presence, amongst others. ABPS: • has an electronic control which allows for automatic switch from electric power supply to battery power supply so that STARLED3 NX can be used as a high performance mobile unit. • is recharged by an automatic charger and requires no specific maintenance. Its autonomy may vary depending on the battery model, which can be from 12 Ah to 28 Ah with maximum charging time of about 8 hours. For more information, please write to: Acem Medical Company Via della Tecnica 29, 40050 Argelato - Bologna – ITALY Phone + 39 051 721844, info@ acem.it, www.acem.it Medical Device ASIA 20 | November-December 2015 | 47


MEDICAL JAPAN (February 24 [Wed] – 26 [Fri], 2016, INTEX Osaka, Japan) is the Japan’s firstever B to B trade show which covers all the products/services/technologies for healthcare (medical devices, hospital supplies), clinical testing, diagnostics and medicines. The previous show hosted 723 exhibitors from 20 countries/regions and attracted 27,692 professionals worldwide, while in 2016, consisted of 6 specialised concurrent shows, it is expected to grow to 1030 exhibitors from 25 countries and 38,000 visitors. Obviously, MEDICAL JAPAN makes a precious meeting spot between top-notch professionals and aspiring companies worldwide to

Now, register yourself for FREE invitation tickets at www.medical-jpn.jp/en/in and receive the latest information from Show Management. To get exhibiting information, please access to www.medical-jpn.jp/en/ex/ or send inquiry e-mails to Show Management at visitor-eng.mj@reedexpo.

generate a new trend of Healthcare and Medical industry.

co.jp

One of the highlights is various conference sessions presented by leading

MEDICAL JAPAN is the best gateway to grabbing the medical industry’s trend and expanding your business in Japan and Asia.

renowned experts. They will share new technologies, market trends, unique business strategies and key to success in their innovative research and development. 250 sessions will be held in appealing and pluggedin lineup – especially one of the Keynote Sessions “The Future Vision of Healthcare in Japan” will be presented by Mr. Shinsuke Kameda, director of Kameda Medical Center, which is Japan’s largest private hospital (excluding university hospitals) and ranked as No.1 in ability of medical care system (according to survey by The Nikkei newspaper in 2013). Kansai, where MEDICAL JAPAN is held, is home to world-class medical research establishments. To make the most of visit, or experience the assets of the area, MEDICAL JAPAN offers exclusive tours to visit some world-class research institutions, such as Center for iPS Cell Research and Application CiRA Kyoto University, directed by Professor Shinya Yamanaka, 2012 Novel Prize laureate and known as Mecca for iPS cell researchers. The tours must be a not-to-be-missed opportunity to sneak secret to stay on the front line in the ever-changing industry. 48 | November-December 2015 | Medical Device ASIA

MEDICAL JAPAN 2016 - 2nd International Medical Expo & Conference Supported by Union of Kansai Governments Organised by Reed Exhibitions Japan Ltd. Venue: INTEX Osaka, Japan Date: February 24 [Wed] – 26 [Fri], 2016 URL: www.medical-jpn.jp/en/ E-mail: medical-japan@reedexpo.co.jp Phone: +81-3-3349-8519

Concurrent shows: - 2nd [Hospital + Innovation] Expo Japan - 1st Medical IT Solutions Expo - Nursing Expo Japan 2016 - 2nd International Nursing & Nursing Care Expo - MEDIX OSAKA 2016 - 6th Medical Device Development Expo Osaka - 2nd Regenerative Medicine Expo & Conference Japan - INTERPHEX OSAKA 2016 - 2nd Int’l Pharmaceutical R&D and Manufacturing Expo Osaka


INTERNATIONAL DIMIMED CONFERENCE ON THE OCCASION OF MEDICA CONFRONTS CURRENT QUESTIONS ON THE CO-OPERATION OF CIVILIAN AND MILITARY MEDICAL FACILITIES

Efficient concentration of competencies in disaster medicine and military medicine

I

n parallel to MEDICA, the world’s largest trade fair for medical technology, the International Conference on Disaster and Military Medicine (DiMiMED) will be held for the third time. This year, the main topic of is operations in crisis areas. In view of the increasing need for humanitarian aid in disaster zones, there is an additional focus on civilian aid organizations and their work. Apart from plenary lectures on innovations and scientific questions in disaster and military medicine, there is an interactive simulation workshop dealing with the practical implementation of aid in major catastrophic events. Additional topics of interest include a session on disaster medicine in international comparison as well as a group of presentations for industry representatives on aspects of the procurement of medical technology by the German Federal Armed Forces and NATO. DiMiMED is held under the patronage of the MEDICAL CORPS INTERNATIONAL FORUM (MCIF) and is organized jointly by Beta Verlag and Messe Düsseldorf. Around 50 international speakers and 200 participants are expected to attend on 17th and 18th November at CCD Süd. MCIF is the only independent magazine aimed

at medial services around the world. An editorial office consisting of topquality professionals offers current articles of international importance from practitioners for practitioners, aimed at professionals in military medicine from more than 180 countries. No matter if we are dealing with military conflicts, terrorist attacks, natural disasters or outbreaks of disease, the world-wide increase of crisis zones needs a sustained longterm management of medical services. In this connection, military medicine offers a broad coverage of medical care. “This year, we have put a strong focus on disaster medicine, since many military medical services world-wide find that this is increasingly developing into a large part of their work, or at least that they have to work in disaster medicine as well as in military operations”, said Rear Admiral uh MC (ret) Christoph Büttner, MD, scientific head of DiMiMED. Within two days, the 200 experts from medicine, industry and logistics will be offered a broad spectrum of information presented and discussed by about 50 internationally respected speakers in plenary lectures and, for the first time, also in

more depth in parallel sessions. Looking back, the second scientific head Brigadier General (ret) Rob van der Meer, MD, says: “I co-chaired the DiMiMED 2014 and saw a fruitful exchange of information and experiences. A shift of interest was evident from operational medical experiences in Asia to Africa. The development of new techniques and future application in the forces was important, both in very simple methods as well as sophisticated procedures and also evaluation processes.” So indeed, a further development of the concept with a more focused approach has already been initiated.

the Deutsche Gesellschaft für Katastrophenmedizin (DGKM, German Society of Disaster Medicine). He gives his opinion on the most urgent issues that need to be broached, both nationally and internationally.

Simulation workshop raises awareness for a major catastrophic event in Dusseldorf

Making procurement processes more transparent to the industry

A special highlight will be the simulation workshop with a scenario of a major catastrophic event. “This simulation was quite consciously ‘placed’ in Dusseldorf, since an event like the Boston assassination can happen anytime and in any city. For the simulation, we have therefore invited, apart from the military guests, high-ranked responsible staff from the ministries of the interior and the police headquarters. My goal is to motivate this target group to conduct similar training scenarios in their area of responsibility – which sometimes is actually done already”, explains Dr. Büttner, thus also referring to the cooperation with CAE Healthcare who are, among others, offering the medical simulation technology. Refugee crisis highlights urgent medical problems The session on “Disaster Medicine & Crisis Prevention” will be chaired by Prof. Leo Latasch, MD, President of

“Medical care for the huge number of refugees world-wide, the question of a joint (!) approach to epidemics and outbreaks of disease, as well as the tasks of the military in a national context for issues like care for refugees and natural disasters, taking into account the question why, if at all, are we always asked so late?”

Last not least: the workshop “Military Procurement for Industry Partners“ will explain procurement processes in military medicine on the example of the German Federal Armed Forces and NATO. The session is especially intended to address industry representatives who want to offer their product portfolio for special military requirements in the home country and in the country of operation. “Basically, we are interested in nearly all areas of medical care and indications. Of course, some fields like paediatrics or geriatrics are not that much in demand, except in rare cases of humanitarian aid after earthquakes or after the tsunami in South East Asia. Emergency and rescue medicine are of course always extremely important – especially under the challenging conditions we meet in our operations abroad” explains Colonel Pharmacist Dr. Ullrich Kindling, Head of Branch U3.5, The Federal Office of Bundeswehr Equipment, Information Technology and In-Service Support..

Medical Device ASIA | November-December 2015 | 49


Kamani Oils receives FDA License

K

amani Oil Industries Pvt. Ltd. announced that they have become the first Indian vegetable oil industry to get a FDA drug license for manufacture of Pharmaceutical grade oils and fats (IP/BP/USP/NF) The initiation of the facility was carried out at Kamani’s Khopoli plant on September 01, 2015. Prakash Chawla, Director, Kamani Oil Industries said, “This is a great achievement and moment of pride for us to be honoured with the license. This gives us impetus to strive for over exceeding the customer expectations who are really special to us. Kamani has been an organisation of many firsts and this certainly is another feather in our cap. This certification will assure our customers about the integrity of our manufacturing process as well as our compliance with the stringent FDA regulations. ”. The chief guest on this auspicious occasion was Mr. Pandita Maharaj – Regional Director Technical Operations, Abbott Health Care Ltd. Some of the other distinguished dignitaries present on this occasion were Assistant Commissioner FDA, PEN (Maharashtra), and other guests from Institute of Chemical Technology, Mumbai, Cipla, Abbott Health Care Ltd., Piramal Healthcare, Fermenta Biotech, Herbinn Micro Medicines. Speaking on this event, Mr. Pandita Maharaj said, “This is a big step for the industry as a whole. Kamani has been the first in the industry to be bestowed with this honour and this

certainly speaks volumes about their stringent processes, reliability and commitment to quality, health and service. This definitely is a landmark in their efforts to supply quality ingredients of global standards to Pharmaceutical and Food Industry and raising the bar. The whole pharmaceutical industry is going to get benefited from this endeavour and will be assured of international quality ingredients indigenously and reducing their dependence on imports. Kamani Oils has made a significant mark in the pharmaceutical and culinary industry over the last 51 years and has now been acknowledged and awarded with its dues by means of the FDA license. Kamani Oils was also the first to become a HACCP, ISO 22000 – now FSSC 22000 certified vegetable oil refinery.

PHARMACEUTICALS, NUTRITION AND COSMETICS SPECIALTY OILS FOR PHARMACEUTICALS We offer a range of specialty oils conforming to IP/BP/USP for pharmaceutical application. They are used as: Carrier system for capsules, soft and hard gels Solvent for oil soluble vitamins, hormones, in injections Solvent for oral suspensions Vehicle for topical preparations like ointments, balms Novel drug delivery system Veterinary vaccine formulations We have introduced a range of exotic vegetable butters which can replace Cocoa butter, Lanolin, some of the animal origin waxes, petroleum based products. They are ideal for: Functional excipients Suppositories and pessaries Tablet coating Lubricant in directly compressible tablets Lipid based drug delivery systems Dermatological preparations- ointment, balm, creams "BETTER SKIN CARE WITH KOSMECARE"

It was the first to procure, manufacture and supply sustainable palm oil, trans free oils and confectionery fats. The manufacturing facility at Khopoli now meets the requirements of Schedule M of the Drugs and Cosmetics act of 1940.

About Kamani Oils Kamani Oils is a leading producer of specialty oils and fats started in 1962. On offer are a wide range of products for specialized applications for the food industry as well as for consumers. Besides speciality products for pharma use, their products include a range of culinary oils, inclusive of speciality fats for Bakery, Confectionary & Frozen Dessert.

50 | November-December 2015 | Medical Device ASIA

After extensive R&D studies, we have recently launched Kosmecare, which is a range of exotic butters and specialty-refined oils to cater to the requirement of various personal care products. The exotic butters are of 100% vegetable origin and are useful for the development of more nature friendly products. These ingredients can replace Cocoa butter, Lanolin, some of the animal origin waxes, petroleum based products, etc that are used in different cosmetic product formulations. Unlike petroleum-based products, they are biodegradable too. These natural vegetable butters are economical quality substitutes for costlier imported material and are most suitable for cost-effective elegant cosmetic products. These find application in development of a whole range of colour cosmetics (Lipsticks, Lip salves, Lip balm, Eye makeup products like Mascara, eye liners kajal sticks etc), Body care, Skin care, Hair care products and Cosmeceuticals. CUSTOM MADE PRODUCTS There are customers who require a very specific functionality in the oil / fat. We are able to tailor make products for these specific requirements.


PITTMAN® Introduces BGE Series Servo Motor Controllers

P

ITTMAN® Motors, a business unit of AMETEK Precision Motion Control, is introducing its latest offering: the BGE Series of Servo Motor Controllers, a family of compact 4-quadrant positioning motion controllers with integral output stage to control Pittman brushless and brushed DC motors.

If 4-quadrant digital speed control is desired, the control can be commanded to run in either direction, stop and hold with torque, and stop without torque (coast) through digital inputs. Other inputs can switch between programmed speeds or allow for a variable analog speed reference.

The motion controllers can be operated in stand-alone operation with digital or analog IO or as a slave in a CANopen network with device profile DSP 402, protocol DS 301. The family of motion controllers is rated from 12VDC to 60VDC input voltage and 4 amp to 20 amp continuous output current.

Accel/decal ramps for the motor also can be programmed. The control offers the capability for a motor to function as a stand-alone or programmed servo, which interfaces to the rest of the machine via digital and analog IO.

The BGE Series controllers are suitable for use with Pittman brushless or brushed DC motors. Information about the motor’s rotor position can be supplied to the positioning controller by an encoder or integrated Hall sensors contained within a brushless motor.

The BGE Series electronic controllers offer many different modes of operation to choose from, such as analog or digital torque control, analog or digital speed control and digitally selectable position control (relative, absolute, and modulo). The controls incorporate protection against over-voltage, low voltage and excessive temperature.

The controls incorporate protection against over-voltage, low voltage and excessive temperature.

Designed for volume OEM applications, BGE Series electronic controllers offer a design alternative

for restricted space applications where the additional length of an integral control motor may not be feasible. They also can be encapsulated to provide additional protection in extreme environmental conditions. If only speed control is required for an application, the BGE 3004A, a costoptimized 1 quadrant controller, is available. BGE controllers are available from stock at the Pittman Express E-Commerce store. For a full listing of available products with associated drawings, specifications and manuals, users can go to www.PittmanExpress.com . For more information, visit www.Pittman-Motors.com or contact an application engineer at 267-933-2105.

About Pittman Pittman is part of the AMETEK Precision Motion Control division. Pittman products are designed into a wide variety of high-tech motion applications, including lab automation, medical devices, communications equipment, semiconductor processing equipment, aerospace systems, and many other applications where precision motion is critical. The Pittman motor line spans a wide variety of DC motor sizes and technologies, ranging from 10 mm-diameter brushless DC motors used in high-speed medical applications to large NEMA frame DC servo motors used in sophisticated automation equipment. Pittman also offers a wide variety of complementary products such as gearboxes, encoders, brakes, and drive systems. For more information, visit www.Pittman-Motors.com. AMETEK Precision Motion Control is a division of AMETEK, Inc., a leading global manufacturer of electronic instruments and electromechanical devices. Medical Device ASIA | November-December 2015 | 51


Introducing a Safer Hand Sanitizer with Lasting Protection! KLENZA – INDIA’S ONLY SILVER ENRICHED ALCOHOL FREE HAND SANITIZER WITH 3 HOUR GERM PROTECTION

A

lways know your hand sanitizer! Most conventional hand sanitizers are alcohol based and stop working the moment you touch something.

But here’s an interesting revelation. Recently launched Klenza, is one of its kind foam based, alcohol free hand sanitizer with a Pure Silver based formulation that is tested as per international standards. Made using a patent pending silver based technology, Klenza actively shields your hands with 99.999% protection against germs. What is more, the natural goodness of the Pure Silver formulation provides continued three hour protection, thus ensuring lasting resistance from germs. Being an alcohol free sanitizer, Klenza is a non-toxic and non-flammable green product that doesn’t use any harmful ingredients like triclosan or paraben etc. Formulated using natural ingredients, this sanitizer can be used at all times without any harmful side effects. Exceptionally gentle and safe on all skin types including kids (3+ years). Unlike conventional alcohol based sanitizers, Klenza does not dry out the skin but instead keeps hands moisturized. Its distinctive foam dispenser pumps small quantities for easier and smoother application. Klenza sanitizers are much safer and ensure 3 hour continued germ protection, making Klenza the best of its kind hand sanitizer. Available in two exquisite fragrances Cool Cologne and Smooth Strawberry, Klenza comes in the 200ml foam pump for Rs. 198 with 250 applications and the 50ml foam pump for Rs. 90 with 120 applications. Klenza hand sanitizers are available in select stores and malls across Bangalore. You can also buy it online at stores like Flipkart, Amazon, FirstCry, PayTm etc.

ABOUT RESIL CHEMICALS PVT LTD:

52 | November-December 2015 | Medical Device ASIA

Resil Chemicals Private Limited is a pioneer of silicone formulations for textile finishing in India and one of Asia’s largest formulators of customized silicones for textile and non-textile applications. Since its inception in 1994, the company has diversified its product range to include specialty chemicals for textile and non-textile applications, emerging technology based products such as hand sanitizers, disinfectants and products for automobile detailing. Today Resil employs more than 300 people and has offices across Asia in India, Thailand, Myanmar, Bangladesh and Sri Lanka. The Company which was founded in Bangalore, India, has grown to meet the technical and scientific requirements of the global market, helping customers to move forward. Resil’s vision is to be an organization that delivers optimum value and satisfaction to all stakeholders and the community at large. The company ensures that the offered products & services are aimed at improving health or user comfort and lifestyle aspirations of the society it serves with adequate environmental care.


Haydon Kerk™ Motion Solutions Introduces Its Latest Addition: Catalyst Motion Group

H

aydon Kerk Motion Solutions, a recognized leader in linear and rotary motion solutions, is pleased to introduce the Catalyst Motion Group as a supplier of integrated motion systems.

manufacturing and engineering that is related specifically to linear and rotary motion systems, Catalyst is uniquely positioned to provide fullservice integrated motion system development, design, test and manufacture.

Catalyst offers custom highprecision linear and rotary motion systems from the very simple to the very complex, and at any level of integration.

Navigating the world of motion control technology can be intimidating, especially since the technology is continually evolving. Catalyst Motion Group can help make sense of the world of motion control and make it accessible through its own expert resources and strategic alignment within the industry.

Catalyst understands the many facets of motion system technology and is focused on harnessing that knowledge to develop next-level application specific solutions. With global resources and an expertise in

More information on Catalyst Motion

Group can be found at its website: www.catalystmotiongroup.com. For help with a specific application, call 1-203-725-3852 or email info.catalyst@ametek.com. Catalyst Motion Group, 1500 Meriden Road, Waterbury, CT 06705. Phone: 203-725-3852. Fax: 203-7568724 About Catalyst Motion Group Catalyst Motion GroupTM is a brand of AMETEK® Precision Motion Control. It offers high-precision linear motion systems at any level of sophistication and integration, providing all necessary mechanical, electrical and software components and support. Its expertise includes

both single-axis and multiple-axis systems that use Haydon, Kerk, Pittman and Dunkermotoren components or are custom designed to client’s specifications. Catalyst brings the resources and support of a global corporation to its customers, who receive individual attention from the single point contact of a small, focused and strategically aligned group. AMETEK Precision Motion Control is a division of AMETEK, Inc., a leading global manufacturer of electronic instruments and electromechanical devices with 2014 annual sales of $4.0 billion.

Medical Device ASIA | November-December 2015 | 53


AV fistula incision for patients undergoing Hemodialysis

K

idney diseases have become a major public health problem which is a leading cause of morbidity and mortality in India and other low- and middle-income countries. Many people who have kidney disease don't know it because the early signs can be very subtle. It can take many years to go from chronic kidney disease (CKD) to kidney failure. Most people with this disease live out their lives without ever reaching kidney failure. Depending on the underlying cause], some types of kidney disease can be treated. Often, though, chronic kidney disease has no cure. In general, treatment consists of measures to help control signs and symptoms, reduce complications, and slow progression of the disease. If your kidneys can't keep up with waste and fluid clearance on their own and you develop complete or near-complete kidney failure, you have end-stage kidney disease. At that point, dialysis or a kidney transplant is needed. Hemodialysis is the most common way to treat advanced kidney failure. “Hemodialysis is a treatment that removes wastes and extra fluid from your blood when your own kidneys have failed. Before hemodialysis can be done, a connection must be made to the blood inside your blood vessels. Your hemodialysis access, or vascular access, is a way to reach your blood for hemodialysis. The access allows your blood to travel

54 | November-December 2015 | Medical Device ASIA

through soft tubes to the dialysis machine where it is cleaned as it passes through a special filter, called a dialyzer. An AV (artery-vein) fistula is the best choice for hemodialysis. It is preferred because it usually lasts longer and has fewer problems like clotting and infections. A fistula should be placed several months before you need to start dialysis. This allows the fistula enough time to be ready for when you need treatment. A fistula (also called an arteriovenous fistula or A-V fistula) is made by joining an artery and a vein under the skin in your arm. When the artery and vein are joined, the pressure inside the vein increases, making the walls of the vein stronger. The stronger vein can then receive the needles used for hemodialysis. . Your wrist or elbow is the preferred location for your

fistula. A fistula will usually last for many years. A fistula usually takes one to four months to “mature” or enlarge before it can be used.” says Dr. Rakesh Mahajan, Head Vascular Surgery, Apollo Hospitals, Delhi. There are two different types of access that can be placed for hemodialysis apart from AV Fistula. They are called, A-V graft, and a Catheter. Minor surgery is needed to create the fistula. Connecting a vein to a nearby artery, usually in your arm, makes it. This creates a large blood vessel that has a fast flow of blood. Your wrist or elbow is the preferred location for your fistula. It’s done under local anesthesia on daycare basis. Infectious complications of the AV fistulas are redness, swelling, soreness, feeling of warmth around your access site; fever, chills, and achy feeling.



Government of India, Registrar of Newspapers of India (RNI)#: DELENG/2009/30008


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.